score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4667	60.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1786	56.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A4F8-06A-11D-A25O-08	TCGA-FS-A4F8-10B-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5	60.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2314	121.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A8YE-06A-11D-A372-08	TCGA-FR-A8YE-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6239	109.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A42Z-01A-12D-A24R-08	TCGA-EB-A42Z-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5195	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A262-06A-11D-A196-08	TCGA-GN-A262-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3902	82.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-HR-A5NC-01A-11D-A27K-08	TCGA-HR-A5NC-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4957	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MH-06A-11D-A197-08	TCGA-EE-A2MH-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1552	58.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3778	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4639	97.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8K6-06A-11D-A372-08	TCGA-WE-A8K6-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6605	162.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F5-06A-11D-A20D-08	TCGA-DA-A3F5-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4857	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6395	147.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A42K-06A-11D-A24R-08	TCGA-ER-A42K-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.29	100.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GB-06A-11D-A372-08	TCGA-D3-A8GB-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4842	95.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-AAZV-01A-11D-A401-08	TCGA-XV-AAZV-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4321	81.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.537	162.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1466	116.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3JE-06A-11D-A20D-08	TCGA-EE-A3JE-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9506	81.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZD-06A-11D-A197-08	TCGA-FS-A1ZD-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3816	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A3DM-01A-11D-A20D-08	TCGA-BF-A3DM-10A-02D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3598	164.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4643	84.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-A9W5-01A-11D-A38G-08	TCGA-XV-A9W5-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3222	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5189	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5ER-01A-12D-A27K-08	TCGA-BF-A5ER-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6519	158.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.382	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7	110.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2M7-06A-11D-A197-08	TCGA-EE-A2M7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6261	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3929	84.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q9-06A-11D-A19A-08	TCGA-D3-A1Q9-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2042	142.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3333	120.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GN-06A-11D-A372-08	TCGA-D3-A8GN-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1748	103.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8577	246.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4923	130.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8113	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3137	102.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JA-06A-11D-A196-08	TCGA-D3-A2JA-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.371	62.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4389	180.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4524	42.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7264	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZS-06A-12D-A197-08	TCGA-FS-A1ZS-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4545	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6301	73.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GB-06A-11D-A197-08	TCGA-EE-A2GB-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.25	128.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1928	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A265-06A-21D-A197-08	TCGA-GN-A265-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5604	182.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U7-06A-21D-A32N-08	TCGA-GN-A4U7-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3077	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6863	51.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MK-06A-11D-A196-08	TCGA-EE-A2MK-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3718	78.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19Q-06A-11D-A197-08	TCGA-ER-A19Q-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7143	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6237	93.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A95W-06A-11D-A372-08	TCGA-DA-A95W-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4851	101.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A1JX-06A-11D-A19A-08	TCGA-D9-A1JX-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.871	93.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-LH-A9QB-06A-11D-A38G-08	TCGA-LH-A9QB-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.381	168.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3J4-06A-11D-A20D-08	TCGA-EE-A3J4-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6	95.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP6-01A-11D-A401-08	TCGA-BF-AAP6-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6324	136.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6667	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6148	122.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6EG-06A-12D-A32N-08	TCGA-D9-A6EG-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4118	85.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A24C-01A-11D-A197-08	TCGA-EB-A24C-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3212	137.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2ND-06A-11D-A196-08	TCGA-ER-A2ND-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3034	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A550-01A-61D-A27K-08	TCGA-EB-A550-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4384	73.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A9SD-06A-11D-A401-08	TCGA-GN-A9SD-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3769	130.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5	152.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.375	168.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5027	185.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3MO-06A-11D-A21A-08	TCGA-D3-A3MO-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.275	80.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3C6-06A-12D-A196-08	TCGA-D3-A3C6-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.475	80.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I2-06A-21D-A19A-08	TCGA-DA-A1I2-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2857	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A148-06A-11D-A19A-08	TCGA-D9-A148-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3727	110.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4111	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.45	140.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GT-01A-12D-A30X-08	TCGA-D3-A5GT-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4189	222.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3MU-06A-11D-A21A-08	TCGA-D3-A3MU-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.398	98.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A85I-01A-11D-A34U-08	TCGA-EB-A85I-10B-01D-A34X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3636	154.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4254	134.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4588	85.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZR-06A-11D-A372-08	TCGA-WE-A8ZR-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6132	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZR-06A-21D-A197-08	TCGA-FS-A1ZR-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.484	188.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3HV-01A-11D-A21A-08	TCGA-EB-A3HV-10B-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5417	168.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A769-01A-32D-A32N-08	TCGA-GF-A769-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5063	79.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2162	74.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.681	163.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5217	138.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5273	110.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4237	118.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP0-06A-11D-A397-08	TCGA-BF-AAP0-10A-01D-A39A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4105	95.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZN-01A-11D-A197-08	TCGA-FS-A1ZN-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3789	161.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9437	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2885	104.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZH-06A-11D-A197-08	TCGA-FS-A1ZH-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3485	66.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2632	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2J7-06A-11D-A196-08	TCGA-D3-A2J7-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4324	148.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2119	118.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GH-06A-11D-A196-08	TCGA-EE-A2GH-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7353	102.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I8-06A-11D-A197-08	TCGA-DA-A1I8-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8462	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19J-06A-11D-A196-08	TCGA-ER-A19J-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3636	99.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-HR-A2OH-06A-11D-A197-08	TCGA-HR-A2OH-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.175	120.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4091	44.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MP-06A-11D-A197-08	TCGA-EE-A2MP-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9535	43.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.507	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3684	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XE-01A-12D-A23B-08	TCGA-EB-A3XE-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9746	118.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2286	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5	74.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.494	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1682	107.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GJ-06A-11D-A372-08	TCGA-D3-A8GJ-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8911	101.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3CE-06A-11D-A19A-08	TCGA-D3-A3CE-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3333	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A17Y-06A-11D-A196-08	TCGA-EE-A17Y-10B-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7547	53.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1YX-06A-11D-A197-08	TCGA-FS-A1YX-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4267	150.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4272	103.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5315	111.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4946	93.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3647	85.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3Y6-01A-21D-A23B-08	TCGA-EB-A3Y6-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7473	182.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5586	111.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1Z7-06A-11D-A197-08	TCGA-FS-A1Z7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4368	174.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9255	161.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.283	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8276	87.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1818	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5704	142.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4247	73.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29W-06A-11D-A196-08	TCGA-EE-A29W-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7304	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4332	187.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A3Z3-06A-11D-A23B-08	TCGA-D9-A3Z3-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4952	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JG-06A-11D-A196-08	TCGA-D3-A2JG-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4672	122.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A4EO-06A-12D-A24R-08	TCGA-GF-A4EO-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1528	72.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8857	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4362	94.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51N-06A-11D-A25O-08	TCGA-D3-A51N-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3158	95.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5841	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A4Z2-01A-11D-A24R-08	TCGA-D9-A4Z2-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5591	127.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.542	131.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2603	73.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6788	137.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A2C7-01A-11D-A197-08	TCGA-GF-A2C7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5323	124.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZM-06A-12D-A197-08	TCGA-FS-A1ZM-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4079	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6604	53.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q5-06A-11D-A196-08	TCGA-D3-A1Q5-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5283	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6418	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1972	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3088	68.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5405	222.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3402	97.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A3DJ-01A-11D-A20D-08	TCGA-BF-A3DJ-10A-02D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2154	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19S-06A-11D-A196-08	TCGA-ER-A19S-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5882	136.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I7-06A-22D-A197-08	TCGA-DA-A1I7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2951	61.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3656	93.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5667	120.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3253	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4091	44.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A4FB-06A-11D-A25O-08	TCGA-FS-A4FB-10B-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6667	102.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6126	111.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4561	57.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3826	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GS-06A-12D-A372-08	TCGA-D3-A8GS-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.322	59.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2087	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A7UA-06A-32D-A34U-08	TCGA-FR-A7UA-10A-01D-A34X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4028	144.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4111	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6E9-06A-12D-A30X-08	TCGA-D9-A6E9-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5641	78.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4394	66.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4603	63.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3372	86.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GD-06A-11D-A372-08	TCGA-D3-A8GD-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4795	146.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A6QZ-01A-12D-A32N-08	TCGA-EB-A6QZ-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4667	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3J3-06A-11D-A20D-08	TCGA-EE-A3J3-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.787	108.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19B-06A-11D-A196-08	TCGA-ER-A19B-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3643	129.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U5-01A-11D-A32N-08	TCGA-GN-A4U5-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3094	139.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A3DN-01A-11D-A20D-08	TCGA-BF-A3DN-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.403	134.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A44A-06A-11D-A24R-08	TCGA-FR-A44A-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4058	69.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3654	104.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6306	157.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8058	139.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3C1-06A-12D-A196-08	TCGA-D3-A3C1-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3913	92.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19C-06A-11D-A196-08	TCGA-ER-A19C-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.425	40.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JD-06A-11D-A19A-08	TCGA-D3-A2JD-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6739	92.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-AAZW-01A-12D-A401-08	TCGA-XV-AAZW-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7927	82.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A20B-06A-11D-A196-08	TCGA-EE-A20B-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2234	94.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4176	170.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5385	78.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A4P0-01A-41D-A25O-08	TCGA-EB-A4P0-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2429	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29P-06A-11D-A197-08	TCGA-EE-A29P-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3889	72.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51J-06A-11D-A25O-08	TCGA-D3-A51J-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3421	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A183-06A-11D-A196-08	TCGA-EE-A183-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3647	85.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3CB-06A-11D-A196-08	TCGA-D3-A3CB-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3048	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.687	131.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A9VF-01A-11D-A372-08	TCGA-BF-A9VF-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4154	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NG-06A-11D-A196-08	TCGA-ER-A2NG-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5571	140.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8571	140.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6211	95.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A299-01A-21D-A197-08	TCGA-EB-A299-10A-01D-A199-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.L576P	0.5	66.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L576P (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A5ES-01A-11D-A27K-08	TCGA-BF-A5ES-10A-01D-A27N-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.5078	128.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A42Y-01A-12D-A24R-08	TCGA-EB-A42Y-10A-01D-A24R-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.4836	304.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A57M-01A-51D-A30X-08	TCGA-EB-A57M-10A-01D-A30X-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.8209	469.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A1Q3-06A-11D-A196-08	TCGA-D3-A1Q3-10A-01D-A198-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.6893	103.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A5KH-06A-11D-A27K-08	TCGA-EB-A5KH-10A-01D-A27N-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559A	0.4094	127.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V559A (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559A	0.2676	71.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V559A (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.W557R	0.7438	121.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.W557R (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.9679	187.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A42H-01A-11D-A24R-08	TCGA-ER-A42H-10A-01D-A24R-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559A	0.1905	84.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V559A (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.L576P	0.9546	551.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L576P (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A51K-06A-11D-A25O-08	TCGA-D3-A51K-10A-01D-A25O-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.5214	117.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.9474	57.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.9231	26.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZG-06A-11D-A197-08	TCGA-FS-A1ZG-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3037	135.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3317	208.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8K1-06A-21D-A372-08	TCGA-WE-A8K1-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4549	244.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7143	224.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13D	0.8687	335.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44R-06A-41D-A25O-08	TCGA-EB-A44R-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4215	121.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I1-06A-12D-A196-08	TCGA-DA-A1I1-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7164	134.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZY-06A-11D-A197-08	TCGA-FS-A1ZY-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6995	183.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.335	200.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZB-06A-12D-A197-08	TCGA-FS-A1ZB-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8571	133.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A1PZ-01A-11D-A19A-08	TCGA-BF-A1PZ-10A-01D-A19A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.454	174.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZY-06A-11D-A372-08	TCGA-WE-A8ZY-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4414	145.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4375	144.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZT-06A-11D-A197-08	TCGA-FS-A1ZT-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4223	296.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.2945	146.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5503	298.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4627	134.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP2-01A-11D-A401-08	TCGA-BF-AAP2-10A-01D-A401-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4494	158.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5939	261.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29X-06A-11D-A196-08	TCGA-EE-A29X-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.8896	163.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6786	140.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5194	206.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13R	0.3701	154.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.8707	116.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.481	79.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A4FD-06A-11D-A25O-08	TCGA-FS-A4FD-10B-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5944	143.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3656	186.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7073	82.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5516	310.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8108	185.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZO-06A-11D-A372-08	TCGA-WE-A8ZO-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8173	104.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8JZ-06A-11D-A372-08	TCGA-WE-A8JZ-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2516	159.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3069	101.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12A	0.4275	138.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12A (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3621	243.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7748	413.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NH-06A-11D-A196-08	TCGA-ER-A2NH-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12D	0.5123	162.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6346	364.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6305	203.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U9-06A-11D-A32N-08	TCGA-GN-A4U9-10B-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5338	133.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5656	122.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1Z0-06A-11D-A197-08	TCGA-FS-A1Z0-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4481	183.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NB-01A-12D-A196-08	TCGA-ER-A2NB-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.1854	178.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6429	210.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3292	1048.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.9124	137.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1Z3-06A-11D-A197-08	TCGA-FS-A1Z3-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3858	127.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12S	0.3598	164.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3561	132.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2408	299.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4375	128.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44Q-06A-11D-A25O-08	TCGA-EB-A44Q-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12R	0.7586	174.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q1-06A-21D-A196-08	TCGA-D3-A1Q1-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7852	256.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A3Z4-01A-11D-A23B-08	TCGA-D9-A3Z4-10A-01D-A23B-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.5522	134.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5269	167.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.6734	349.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.771	131.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.5399	276.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8605	129.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.487	115.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5599	284.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6194	155.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3581	148.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.9061	245.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5963	322.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5357	308.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.6585	164.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7202	336.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6852	216.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A7U8-06A-21D-A34U-08	TCGA-FR-A7U8-10A-01D-A34X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6032	189.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-HR-A2OG-06A-21D-A197-08	TCGA-HR-A2OG-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13R	0.391	133.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2781	151.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A1NK-01A-11D-A196-08	TCGA-EB-A1NK-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3212	137.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4486	107.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-AAA3-06A-11D-A38G-08	TCGA-WE-AAA3-10A-01D-A38J-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7972	503.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5VU-01A-21D-A32N-08	TCGA-EB-A5VU-10A-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.612	183.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6442	163.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51E-06A-11D-A25O-08	TCGA-D3-A51E-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3033	122.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2273	154.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5889	287.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.2569	109.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.479	167.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29Q-06A-11D-A197-08	TCGA-EE-A29Q-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.6327	422.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4638	138.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-AAZY-01A-12D-A401-08	TCGA-XV-AAZY-10A-01D-A401-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.3333	105.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.2727	55.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.3945	109.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A42H-01A-11D-A24R-08	TCGA-ER-A42H-10A-01D-A24R-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.4211	114.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Putatively Actionable	Preclinical	Preclinical		Somatic Variant	MAP2K1	Missense	p.Q56P	0.5865	133.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Vemurafenib	B-RAF inhibition	Targeted therapy	Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.Q56P (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.4516	62.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2267	75.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.6154	39.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.3824	34.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.3429	35.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.K700E	0.3036	56.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K700E (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.1774	62.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.451	51.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A690-06A-11D-A30X-08	TCGA-RP-A690-10A-01D-A30X-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.2432	37.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A2NF-01A-11D-A19A-08	TCGA-ER-A2NF-10A-01D-A19A-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.N626Y	0.2929	99.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.N626Y (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Putatively Actionable			Guideline	Somatic Variant	SETBP1	Missense	p.E858K	0.2955	44.0	0.0	0.0																Putatively Actionable	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E858K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.6977	43.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A3ES-06A-11D-A20D-08	TCGA-ER-A3ES-10A-01D-A20D-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4062	64.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U8-06A-21D-A34U-08	TCGA-FR-A7U8-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5	60.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P731S	0.632	269.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P731S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.5259	116.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H725Y	0.4828	116.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H725Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-3N-A9WB-06A-11D-A38G-08	TCGA-3N-A9WB-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4146	82.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3816	76.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A3DM-01A-11D-A20D-08	TCGA-BF-A3DM-10A-02D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3576	165.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.N581S	0.5542	83.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N581S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3258	89.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5143	105.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5ER-01A-12D-A27K-08	TCGA-BF-A5ER-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3636	88.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.N581T	0.1795	39.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N581T (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A1JW-06A-11D-A19A-08	TCGA-D9-A1JW-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.3256	129.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4524	42.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6301	73.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GB-06A-11D-A197-08	TCGA-EE-A2GB-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.7143	70.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.4321	81.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6377	138.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L597Q	0.3853	109.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L597Q (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P367S	0.3623	138.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P367S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.2308	91.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.4103	78.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S467L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4967	153.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3614	166.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.4239	92.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H235Y	0.5526	76.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H235Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H725Y	0.3008	236.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H725Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3618	152.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.3583	307.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3484	310.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.6941	85.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6941	85.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.2906	117.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4237	118.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP0-06A-11D-A397-08	TCGA-BF-AAP0-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.8462	65.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19J-06A-11D-A196-08	TCGA-ER-A19J-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.9746	118.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2222	72.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5062	81.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4238	151.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.N581H	0.4857	70.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N581H (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A4Z5-01A-11D-A25O-08	TCGA-D9-A4Z5-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469R	0.369	84.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.8243	74.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1QA-06A-11D-A196-08	TCGA-D3-A1QA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.8378	74.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1QA-06A-11D-A196-08	TCGA-D3-A1QA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.8256	86.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.5174	172.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5816	141.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5597	134.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2432	74.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.R726C	0.411	146.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.R726C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.617	141.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6259	139.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.543	221.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P348T	0.4058	138.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P348T (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3548	93.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5714	119.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6634	101.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.5118	127.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L245F	0.4865	37.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L245F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3443	61.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2105	114.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A7UA-06A-32D-A34U-08	TCGA-FR-A7UA-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.2751	189.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L485F	0.5469	64.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L485F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2128	94.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4083	169.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3562	73.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A183-06A-11D-A196-08	TCGA-EE-A183-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H574Y	0.3571	42.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H574Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.2581	62.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S467L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P192S	0.2344	64.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P192S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P272L	0.2667	75.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P272L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D379N	0.461	141.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D379N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E400K	0.3235	102.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E400K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.M650I	0.2857	147.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.M650I (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P699L	0.3816	207.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P699L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L782F	0.3149	181.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L782F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G917R	0.2703	148.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G917R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L541F	0.2694	193.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L541F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E114K	0.3412	85.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E114K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P1178L	0.2143	28.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P1178L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S447F	0.41	100.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S447F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.E1180*	0.3929	56.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E1180* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.K737E	0.9778	45.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.K737E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G983R	0.3383	133.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G983R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S227F	0.3921	227.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S227F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S364F	0.1947	113.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S364F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P934S	0.2048	83.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P934S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R958C	0.2169	166.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R958C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.Q982*	0.25	80.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q982* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P589L	0.3879	116.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P589L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.N604D	0.3727	110.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.N604D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E922K	0.2807	114.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E922K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D1009N	0.3846	143.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D1009N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.Q581*	0.5584	77.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q581* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L101F	0.3868	106.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L101F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D368N	0.2317	82.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D368N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P100S	0.4422	199.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P100S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S116F	0.4387	155.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S116F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P622S	0.2593	54.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P622S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P753S	0.16	75.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P753S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.Q982*	0.4896	96.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q982* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R49C	0.225	40.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R49C (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.P426S	0.4118	85.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.P426S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.T666I	0.3106	132.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.T666I (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R456S	0.1829	82.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R456S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.Y641N	0.4	25.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.Y641N (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.Y641F	0.1633	49.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.Y641F (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A1JW-06A-11D-A19A-08	TCGA-D9-A1JW-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R216Q	0.3354	164.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R216Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.G137E	0.9688	64.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.G137E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.D142V	0.3582	67.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.D142V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.T245M	0.2614	88.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.T245M (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.S451C	0.9189	37.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S451C (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5SH-06A-11D-A30X-08	TCGA-EB-A5SH-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.S123F	0.3333	33.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S123F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S228F	0.4229	175.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S228F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41B-01A-11D-A24R-08	TCGA-EB-A41B-10A-01D-A24R-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822I	0.9733	225.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.Y641N	0.4024	82.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.Y641N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S533L	0.6571	70.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S533L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.C530W	0.2653	49.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.C530W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S405L	0.1912	408.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S405L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.P363S	0.45	20.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.P363S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822K	0.6374	182.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822K (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A264-06A-11D-A196-08	TCGA-GN-A264-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.T4I	0.369	355.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.T4I (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.T4P	0.3665	352.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.T4P (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.L706F	0.4239	92.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L706F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.P132S	0.3409	44.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.P132S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.L338F	0.3462	234.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.L338F (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.H274Y	0.4538	390.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.H274Y (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A1X3-06A-11D-A197-08	TCGA-D9-A1X3-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.E686K	0.25	44.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.E686K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.Q1017*	0.3239	71.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.Q1017* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.S796*	0.508	250.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.S796* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G137E	0.3333	24.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G137E (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P696L	0.2206	68.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P696L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S787F	0.2343	175.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S787F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P62L	0.2115	156.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P62L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.D576N	0.6379	58.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.D576N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S679F	0.2581	31.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S679F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P699L	0.5263	38.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P699L (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-AA3S-06A-11D-A397-08	TCGA-Z2-AA3S-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S130F	0.3333	21.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S130F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P63S	0.5981	107.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P63S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P1027L	0.3778	90.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P1027L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.T440M	0.37	100.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.T440M (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A42Z-01A-12D-A24R-08	TCGA-EB-A42Z-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P6Q	0.2629	194.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P6Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K702M	0.3488	43.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.K702M (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P519S	0.8788	33.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P519S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A1PZ-01A-11D-A19A-08	TCGA-BF-A1PZ-10A-01D-A19A-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G662R	0.383	47.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G662R (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L891F	0.4359	117.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L891F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E229K	0.3871	155.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E229K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1085K	0.519	158.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1085K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E63K	0.2333	210.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E63K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L161V	0.203	133.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L161V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E459K	0.3147	143.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E459K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S890F	0.2692	78.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S890F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P414S	0.1964	56.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P414S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.H425Y	0.2319	138.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.H425Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S470L	0.2188	128.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S470L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D691N	0.2115	104.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D691N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D480N	0.4179	67.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D480N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E996K	0.5493	71.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E996K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R748K	0.6136	44.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R748K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.I888N	0.47	100.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.I888N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1Z3-06A-11D-A197-08	TCGA-FS-A1Z3-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L506F	0.4127	63.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L506F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P345S	0.5574	61.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P345S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P155L	0.3182	66.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P155L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.A7T	0.2471	174.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.A7T (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L790P	0.4074	108.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L790P (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P895L	0.322	59.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P895L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.N907T	0.475	40.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.N907T (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R72K	0.3979	191.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R72K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1068K	0.4128	109.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1068K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.H477Y	0.5816	98.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.H477Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E331K	0.5057	87.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E331K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29Q-06A-11D-A197-08	TCGA-EE-A29Q-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D706N	0.3793	87.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D706N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.K117N	0.2411	112.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.K117N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.E62K	0.44	25.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.E62K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61R	0.44	25.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61L	0.6053	76.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12R	0.4286	14.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61K	0.4659	88.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.2281	57.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-A9W2-01A-11D-A397-08	TCGA-XV-A9W2-10A-01D-A39A-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.E63K	0.3412	85.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.E63K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3548	31.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2325_splice	0.5	40.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2325_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EB-A57M-01A-51D-A30X-08	TCGA-EB-A57M-10A-01D-A30X-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q2433*	0.7273	11.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q2433* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MN-06A-11D-A197-08	TCGA-EE-A2MN-10A-01D-A199-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R35*	0.6721	61.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R35* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A82C-01A-11D-A34U-08	TCGA-EB-A82C-10B-01D-A34X-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D1000N	0.395	119.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D1000N (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R1050Q	0.4407	59.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R1050Q (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q1562*	0.3546	141.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q1562* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P1049S	0.4184	141.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P1049S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D627N	0.3684	19.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D627N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GD-06A-11D-A196-08	TCGA-EE-A2GD-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R417C	0.6842	19.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R417C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D322N	0.283	53.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D322N (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P155S	0.561	41.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P155S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M970I	0.3846	78.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M970I (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q2870*	0.4681	47.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2870* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G823E	0.4019	311.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G823E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R912Q	0.2972	1043.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R912Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E62K	0.4545	44.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E62K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G823E	0.2549	51.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G823E (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A741T	0.4051	195.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A741T (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.T92I	0.4	30.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.T92I (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E480K	0.2609	46.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E480K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D698N	0.3182	22.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D698N (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P320S	0.44	25.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P320S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E366Q	0.3878	49.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E366Q (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2984	124.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.7991	229.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-3N-A9WB-06A-11D-A38G-08	TCGA-3N-A9WB-10A-01D-A38J-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3516	128.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5106	141.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.7405	289.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q22K	0.5362	69.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q22K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.6047	382.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.192	125.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GD-06A-11D-A196-08	TCGA-EE-A2GD-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.P34L	0.9298	57.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.P34L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8798	183.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.43	293.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4481	183.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3687	179.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A268-06A-11D-A196-08	TCGA-GN-A268-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3583	187.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.365	137.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MN-06A-11D-A197-08	TCGA-EE-A2MN-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2632	152.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3047	128.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4076	211.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8235	102.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8JZ-06A-11D-A372-08	TCGA-WE-A8JZ-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.9035	114.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A185-06A-11D-A196-08	TCGA-EE-A185-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4751	181.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3724	196.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A267-06A-21D-A196-08	TCGA-GN-A267-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3684	152.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A85J-01A-12D-A34U-08	TCGA-EB-A85J-10B-01D-A34X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3577	246.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3165	218.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3127	259.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GL-06A-11D-A196-08	TCGA-EE-A2GL-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4342	152.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A2NE-06A-21D-A196-08	TCGA-ER-A2NE-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2797	118.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A195-06A-11D-A196-08	TCGA-ER-A195-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4451	173.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZE-06A-11D-A197-08	TCGA-FS-A1ZE-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.7602	342.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19D-06A-11D-A197-08	TCGA-ER-A19D-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8276	203.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.419	401.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4891	137.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.6707	82.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5789	171.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3386	189.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JO-06A-11D-A196-08	TCGA-D3-A2JO-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4497	189.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1YW-06A-11D-A197-08	TCGA-FS-A1YW-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.R366Q	0.2881	59.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.R366Q (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E1258K	0.2073	82.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E1258K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E139K	0.4	145.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E139K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A42K-06A-11D-A24R-08	TCGA-ER-A42K-10A-01D-A24R-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.Y46D	0.2297	148.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.Y46D (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R138W	0.3393	56.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R138W (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P1170L	0.3086	81.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P1170L (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5ES-01A-11D-A27K-08	TCGA-BF-A5ES-10A-01D-A27N-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R695C	0.3158	76.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R695C (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1185*	0.9355	31.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1185* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L403P	0.4706	34.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L403P (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L755M	0.463	54.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L755M (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S426F	0.3398	103.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S426F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P381L	0.3359	131.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P381L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E645K	0.3514	74.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E645K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.R245*	0.575	40.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.R245* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.R751*	0.338	142.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.R751* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G342E	0.375	80.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G342E (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P291L	0.28	50.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P291L (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.R1138*	0.2632	152.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.R1138* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.Q516*	0.25	56.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Q516* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G81E	0.3228	127.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G81E (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S243F	0.3117	77.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S243F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S140F	0.2476	105.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S140F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.L701F	0.4045	89.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.L701F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S407L	0.5192	52.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S407L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.A293V	0.4416	77.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.A293V (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S140F	0.5	20.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S140F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.H532Y	0.3083	133.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.H532Y (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y1063*	0.4248	153.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1063* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.L804*	0.3588	131.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L804* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Nonsense	p.Q424*	0.5952	42.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.Q424* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.P182L	0.4045	89.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.P182L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S1178F	0.2258	62.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S1178F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R710*	0.7273	88.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R710* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.S214F	0.4571	105.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.S214F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y85*	0.7755	49.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y85* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G1097E	0.5909	66.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G1097E (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.V232F	0.2812	32.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.V232F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K717*	0.3108	74.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K717* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.W1183*	0.45	40.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.W1183* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-ER-A2NG-06A-11D-A196-08	TCGA-ER-A2NG-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.D228V	0.381	63.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.D228V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.E256*	0.4615	26.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E256* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X342_splice	0.6182	55.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X342_splice (Splice Site)	1	SKCM_SOMATICSNIPER	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.W274*	0.7857	42.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.W274* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q298*	0.254	63.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q298* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X70_splice	0.7619	21.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X70_splice (Splice Site)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R130*	0.7667	60.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q298*	0.4878	41.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q298* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q87*	0.3232	99.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q87* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P211S	0.375	56.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P211S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S50L	0.2295	61.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S50L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.N609Y	0.3571	84.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.N609Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P986S	0.2597	77.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P986S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.D248N	0.3709	151.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.D248N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S201L	0.2846	130.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S201L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E77K	0.3	140.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E77K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E266K	0.1685	89.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E266K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.3238	105.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.F53I	0.2911	158.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.F53I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P888S	0.3889	18.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P888S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.N122K	0.4048	42.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.N122K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E573K	0.2258	31.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E573K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.K57N	0.6213	235.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.K57N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V56I	0.3067	75.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V56I (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E880K	0.449	49.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E880K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.3023	86.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.R387Q	0.141	78.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.R387Q (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44N-01A-11D-A25O-08	TCGA-EB-A44N-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S111A	0.3465	101.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S111A (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3J4-06A-11D-A20D-08	TCGA-EE-A3J4-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.F373L	0.4571	105.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.F373L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.L131V	0.4359	78.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.L131V (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.D398N	0.3041	171.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.D398N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S941L	0.2353	102.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S941L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203K	0.2357	157.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3JH-06A-11D-A21A-08	TCGA-EE-A3JH-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V843A	0.3708	89.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V843A (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E360K	0.4839	62.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E360K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S618L	0.4623	106.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S618L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.3663	101.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.2593	54.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S993L	0.1818	66.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S993L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.2727	55.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203V	0.2892	166.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E880K	0.2254	142.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E880K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P937S	0.2931	58.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P937S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MP-06A-11D-A197-08	TCGA-EE-A2MP-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G414E	0.4245	106.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G414E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.1846	65.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P534S	0.25	32.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P534S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E991K	0.4462	65.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E991K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S127F	0.2174	46.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S127F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E775K	0.5647	85.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E775K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.N122D	0.4634	82.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.N122D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G905V	0.6364	11.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G905V (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S618L	0.3264	239.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S618L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A3Z3-06A-11D-A23B-08	TCGA-D9-A3Z3-10A-01D-A23B-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P391S	0.5443	79.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P391S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203K	0.1977	86.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A1Q8-06A-11D-A19A-08	TCGA-D3-A1Q8-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.G294E	0.2857	70.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.G294E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.4833	60.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.4754	61.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S941L	0.3258	89.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S941L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.2857	63.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V129I	0.3654	52.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V129I (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.M176L	0.2532	79.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.M176L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.29	100.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A3DN-01A-11D-A20D-08	TCGA-BF-A3DN-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L118V	0.4407	59.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.L118V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-XV-AAZW-01A-12D-A401-08	TCGA-XV-AAZW-10A-01D-A401-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.M176I	0.2273	44.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.M176I (Missense)	1	SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.Y597N	0.3611	36.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.Y597N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G613E	0.4365	181.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G613E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N1544D	0.3461	419.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N1544D (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N411H	0.3976	83.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N411H (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D633N	0.3421	76.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.D633N (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G952E	0.3059	170.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G952E (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E296K	0.2991	214.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E296K (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.H682Y	0.4194	31.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.H682Y (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1242K	0.3571	56.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E1242K (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1269E	0.4079	76.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1269E (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G410E	0.3214	84.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G410E (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A1200V	0.4	35.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A1200V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G359E	0.3562	160.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G359E (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1304E	0.2885	104.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1304E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G667E	0.2597	77.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G667E (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P547L	0.3235	34.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P547L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G558V	0.1977	86.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G558V (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1494E	0.2097	186.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1494E (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P1355L	0.2857	133.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P1355L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G869E	0.2481	129.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G869E (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G869R	0.2481	129.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G869R (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S277F	0.264	125.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S277F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E668K	0.2174	92.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E668K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P675L	0.8188	138.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P675L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R401Q	0.2985	67.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R401Q (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G747E	0.2826	46.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G747E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M910I	0.1944	36.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M910I (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N424S	0.2	45.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N424S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A586V	0.2881	59.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A586V (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S319F	0.4898	49.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S319F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P381L	0.5636	55.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P381L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G914R	0.6444	45.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G914R (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M1615I	0.3519	54.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M1615I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E483K	0.5354	127.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E483K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G574E	0.3148	54.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G574E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.L601F	0.3065	62.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.L601F (Missense)		SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G558E	0.2632	76.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G558E (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.H458Y	0.3763	93.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.H458Y (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G562E	0.4342	76.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G562E (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G903E	0.1905	42.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G903E (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G391E	0.2828	99.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G391E (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G935V	0.3469	147.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G935V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G922R	0.3333	36.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G922R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P968L	0.2125	160.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P968L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1110K	0.6111	36.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E1110K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1011E	0.2857	105.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1011E (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G818R	0.3049	82.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G818R (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S295F	0.3578	109.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S295F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E296K	0.4918	122.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E296K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E737K	0.4133	75.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E737K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R818C	0.2727	33.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R818C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S773F	0.2394	142.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.S773F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P57L	0.2154	65.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P57L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G865D	0.3636	22.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G865D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.D746Y	0.2676	71.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.D746Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.F958S	0.2885	52.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.F958S (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S512L	0.4643	28.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S512L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P743L	0.4824	85.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P743L (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1200*	0.4118	51.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1200* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1401*	0.193	57.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1401* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R2158*	0.3654	104.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2158* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.Y933F	0.3571	140.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.Y933F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S398F	0.2759	87.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S398F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q789*	0.3571	70.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q789* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L150F	0.3125	64.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L150F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1528*	0.1688	77.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1528* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S102F	0.3043	23.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S102F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E890D	0.5556	18.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E890D (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q920*	0.5506	89.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q920* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P430S	0.4538	119.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P430S (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L686F	0.205	161.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L686F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.D684N	0.2331	163.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.D684N (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G282E	0.5	28.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G282E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.G155S	0.3448	29.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.G155S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E76K	0.2564	39.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E76K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.P319S	0.271	107.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.P319S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.H500Y	1.0	50.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.H500Y (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A262-06A-11D-A196-08	TCGA-GN-A262-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1148Q	0.1446	83.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1148Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2272K	0.3448	29.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2272K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2295K	0.3247	77.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2295K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.H355Y	0.5285	123.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.H355Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A3F5-06A-11D-A20D-08	TCGA-DA-A3F5-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.V256I	0.3617	94.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.V256I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P2759S	0.3704	135.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.P2759S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.C430S	0.4333	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.C430S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Nonsense	p.R978*	0.6562	32.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R978* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.H194Y	0.5526	38.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.H194Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1ZD-06A-11D-A197-08	TCGA-FS-A1ZD-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.S238L	0.1786	28.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.S238L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A5ES-01A-11D-A27K-08	TCGA-BF-A5ES-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R274P	0.3471	121.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R274P (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S516R	0.1818	33.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S516R (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A1JW-06A-11D-A19A-08	TCGA-D9-A1JW-10A-01D-A19A-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G460D	0.1781	73.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G460D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.V557I	0.2962	422.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.V557I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G600E	0.2759	58.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G600E (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZS-06A-12D-A197-08	TCGA-FS-A1ZS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S182F	1.0	5.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S182F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.M937I	0.283	106.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.M937I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S653F	0.4709	223.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S653F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.P93S	0.7037	27.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.P93S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E17K	0.381	21.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E17K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V158A	0.6471	204.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V158A (Missense)	0	SKCM_SOMATICSNIPER	TCGA-LH-A9QB-06A-11D-A38G-08	TCGA-LH-A9QB-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.K2363N	0.7727	22.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.K2363N (Missense)	1	SKCM_SOMATICSNIPER	TCGA-LH-A9QB-06A-11D-A38G-08	TCGA-LH-A9QB-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R547Q	0.3248	157.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R547Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.A1109V	0.3776	98.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.A1109V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.5263	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.F241L	0.34	50.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.F241L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R457Q	0.3814	97.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R457Q (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.G161V	0.4153	183.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.G161V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A185-06A-11D-A196-08	TCGA-EE-A185-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.2222	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G429E	0.3429	70.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G429E (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S601F	0.3902	41.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S601F (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V2937G	0.3301	209.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V2937G (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.G311D	0.5397	63.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.G311D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1279K	0.2867	429.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1279K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.E588K	0.3462	52.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.E588K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E76K	0.4762	105.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E76K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G436E	0.3158	19.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G436E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.A330V	0.3615	3026.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.A330V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2623F	0.9688	32.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2623F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G1057D	0.8462	13.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G1057D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G1057S	0.8462	13.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G1057S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.D972N	0.2581	62.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.D972N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E132K	0.4478	67.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E132K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E131D	0.4478	67.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E131D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P373S	0.2684	190.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P373S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.M630I	0.4043	188.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.M630I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G694E	0.2865	171.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G694E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.M1160I	0.5565	115.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.M1160I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.H1351Y	0.5198	177.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.H1351Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V462A	0.3049	82.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V462A (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P373S	0.3649	211.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P373S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2526K	0.28	25.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2526K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P2056S	0.2609	23.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.P2056S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R613Q	0.3846	52.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R613Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S1947Y	0.8222	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S1947Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.C533R	0.4762	126.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.C533R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P298L	0.3667	60.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P298L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H290Y	0.2308	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H290Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.P176S	0.2692	52.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.P176S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S135N	0.2077	313.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S135N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P1366S	0.4097	144.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P1366S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G221E	0.2889	45.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G221E (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P843S	0.541	122.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P843S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E994K	0.5517	58.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E994K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P1013S	0.4231	104.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P1013S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E1388K	0.2778	162.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E1388K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P1311L	0.4745	137.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P1311L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1312K	0.5556	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1312K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R549Q	0.4802	177.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R549Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S2168L	0.4306	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S2168L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S213L	0.3684	190.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S213L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D912N	0.6667	21.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D912N (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.S447F	0.3036	224.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.S447F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E601K	0.32	100.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E601K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2691C	0.2449	49.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2691C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E567K	0.3684	228.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E567K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.S56F	0.6667	81.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.S56F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.L679V	0.1604	106.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.L679V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.3421	76.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R469Q	0.3667	180.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R469Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H2099Y	0.5694	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H2099Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G109E	0.2381	105.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G109E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.T180S	0.5188	160.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.T180S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1148Q	0.2935	201.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1148Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.L49V	0.6429	14.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.L49V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P1069S	0.6098	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.P1069S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P418S	0.3029	175.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P418S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A1323V	0.3185	135.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1323V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1915H	0.4	100.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L1915H (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G963R	0.4348	138.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G963R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.D911N	0.5	10.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.D911N (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.N1036K	0.2097	62.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.N1036K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D42N	0.6111	90.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D42N (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L607F	0.2979	47.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L607F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.I307V	0.5333	15.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.I307V (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1382C	0.8553	76.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1382C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S73L	0.2381	42.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.S73L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R126C	0.34	50.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R126C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D647N	0.1633	49.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D647N (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A85J-01A-12D-A34U-08	TCGA-EB-A85J-10B-01D-A34X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.S1687F	0.3333	63.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.S1687F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.P208L	0.321	81.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.P208L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.A215G	0.6452	62.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.A215G (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D392G	0.4105	95.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D392G (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1919S	0.3462	52.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1919S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1549S	0.2151	93.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1549S (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.L406F	0.4052	153.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.L406F (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A760V	0.4019	428.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A760V (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.L226F	0.2154	65.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.L226F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R623W	0.2451	102.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R623W (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R553C	0.4302	86.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R553C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1164L	0.1889	90.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1164L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S215R	0.3667	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S215R (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.3125	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.8108	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.6429	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.6923	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A1Q0-01A-21D-A19A-08	TCGA-BF-A1Q0-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.6591	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.2857	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.86	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D48N	0.5851	834.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D48N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P177L	0.5714	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P177L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.4876	121.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.5	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP2-01A-11D-A401-08	TCGA-BF-AAP2-10A-01D-A401-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.7857	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278L	0.7083	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29X-06A-11D-A196-08	TCGA-EE-A29X-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P27L	0.5065	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.4615	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P27S	0.2222	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V143E	0.7209	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.7	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110P	0.7667	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110P (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P191L	0.381	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P191L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P152L	0.378	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.9	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.C275*	0.7391	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E198*	0.6667	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E198* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.55	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R290C	0.5135	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R290C (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.4314	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.4636	110.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.8	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.6533	375.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.4167	108.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C141G	0.3333	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141G (Missense)		SKCM_SOMATICSNIPER	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G187S	0.3585	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G187S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P72S	0.271	155.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P72S (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.5694	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.403	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.6923	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L330R	0.65	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L330R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8507	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.7609	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F134L	0.35	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F134L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V143G	0.9429	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143G (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K120E	0.52	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K120E (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F134L	0.95	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F134L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.8627	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A3ET-06A-11D-A20D-08	TCGA-ER-A3ET-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.2	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.8158	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8605	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Y327*	0.9167	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y327* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.9076	119.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P27S	0.9153	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27S (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278S	0.4348	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278S (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.6667	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.9841	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.3571	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213Q	0.6	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S127F	0.2051	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S127F (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.623	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.5312	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.2632	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.9412	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2125	80.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A299-01A-21D-A197-08	TCGA-EB-A299-10A-01D-A199-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A206V	0.4	110.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A206V (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P561S	0.4098	61.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P561S (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S742F	0.275	40.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S742F (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.T277I	0.3966	58.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.T277I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A206V	0.6905	42.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A206V (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S709F	0.3529	51.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S709F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S420F	0.3654	52.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S420F (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.G303R	0.5	14.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.G303R (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A148-06A-11D-A19A-08	TCGA-D9-A148-10A-01D-A19A-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P971S	0.2991	117.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P971S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P1108L	0.4839	31.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P1108L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R764G	0.2857	84.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R764G (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A2NE-06A-21D-A196-08	TCGA-ER-A2NE-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P918L	0.2857	35.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P918L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P310T	0.2108	166.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P310T (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P310L	0.2048	166.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P310L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P551L	0.4286	35.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P551L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.P381L	0.2903	31.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.P381L (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.G578R	0.3556	90.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.G578R (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.M833I	0.7143	28.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.M833I (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R787Q	0.7468	79.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R787Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E669K	0.8889	18.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E669K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.D71N	0.3895	172.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.D71N (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.D71N	0.3951	81.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.D71N (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E541K	0.8485	33.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E541K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D605N	0.6604	53.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D605N (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E645K	0.5455	11.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E645K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D696N	0.275	40.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D696N (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D605N	0.44	25.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D605N (Missense)		SKCM_SOMATICSNIPER	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E238K	0.25	28.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E238K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57L	0.5062	81.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57L (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57V	0.2389	180.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57V (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D733N	0.1702	47.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D733N (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.P291L	0.3846	13.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P291L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.P291S	0.3846	13.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P291S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.T919I	0.6842	38.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.T919I (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G176E	0.3542	192.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G176E (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E979K	0.3429	175.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E979K (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S1443L	0.3514	37.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S1443L (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E1160K	0.2745	51.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E1160K (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.E428K	0.4043	94.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E428K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A630G	0.5294	136.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A630G (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Nonsense	p.W153*	0.9273	110.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.W153* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P106L	0.1964	112.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P106L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.S229F	0.2734	128.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.S229F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Nonsense	p.R378*	0.6667	87.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R378* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P198S	0.3509	57.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P198S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.M1060I	0.3684	57.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.M1060I (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.G685E	0.2727	88.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.G685E (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D894G	0.3409	44.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D894G (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P1003S	0.25	164.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1003S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Splice Site	p.X1080_splice	0.2039	103.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.X1080_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L174F	0.1942	206.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L174F (Missense)		SKCM_SOMATICSNIPER	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S606F	0.1628	86.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S606F (Missense)		SKCM_SOMATICSNIPER	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L1173F	0.1724	87.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L1173F (Missense)		SKCM_SOMATICSNIPER	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D925E	0.3529	68.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D925E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S1282R	0.2329	73.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S1282R (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K267E	0.3333	63.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K267E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P453L	0.2482	137.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P453L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P453S	0.2409	137.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P453S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A1217V	0.6	50.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A1217V (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.H649Y	0.3556	45.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.H649Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P812S	0.3077	91.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P812S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P351L	0.25	84.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P351L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P351S	0.2561	82.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P351S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P462S	0.3889	90.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P462S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.Y898H	0.2267	75.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.Y898H (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D564E	0.6154	52.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D564E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R987W	0.4509	173.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R987W (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R184K	0.2982	57.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R184K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S886L	0.186	43.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S886L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P742L	0.875	8.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P742L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P563S	0.2888	232.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P563S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P491S	0.4054	148.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P491S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R1033*	0.7368	57.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R1033* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G1045E	0.2903	31.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G1045E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D76N	0.5349	86.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D76N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P563S	0.2511	223.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P563S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P274L	0.3123	269.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P274L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y6-01A-21D-A23B-08	TCGA-EB-A3Y6-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A361T	0.3649	74.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A361T (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E1352K	0.2542	59.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E1352K (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.Y448H	0.3828	303.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Y448H (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P370L	0.2824	85.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P370L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P228S	0.4	55.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P228S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.R1297C	0.4103	39.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R1297C (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R626Q	0.4364	55.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R626Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P983S	0.4186	129.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P983S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G638R	0.3049	82.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G638R (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P405S	0.2083	48.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P405S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.H1256Y	0.4444	18.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.H1256Y (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P49S	0.25	20.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P49S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E599K	0.2093	43.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E599K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G821E	0.8491	53.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G821E (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L1197F	0.2478	113.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L1197F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P742L	0.4773	44.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P742L (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P1255L	0.5278	36.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1255L (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R749C	0.2281	114.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R749C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A1-06A-11D-A197-08	TCGA-EE-A2A1-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P1255L	0.4423	52.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1255L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S944N	0.1875	64.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S944N (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P115L	0.2931	58.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P115L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S259F	0.2133	75.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S259F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29P-06A-11D-A197-08	TCGA-EE-A29P-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Splice Site	p.X866_splice	0.3103	29.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.X866_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A51J-06A-11D-A25O-08	TCGA-D3-A51J-10A-01D-A25O-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D61N	0.2083	48.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D61N (Missense)		SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R530Q	0.3333	147.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R530Q (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P566L	0.4552	290.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P566L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P76S	0.2195	41.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P76S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P279L	0.6842	57.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.P279L (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D908N	0.4917	120.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D908N (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D1628E	0.6111	18.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D1628E (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1091L	0.4286	161.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1091L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U7-06A-21D-A32N-08	TCGA-GN-A4U7-10B-01D-A32N-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1101S	0.5484	31.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1101S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S126N	0.4028	72.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S126N (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S259L	0.8571	7.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S259L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.L1047I	0.3415	41.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.L1047I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S1115F	0.2848	151.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S1115F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.Q1587H	0.7083	24.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.Q1587H (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R487C	0.3537	82.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R487C (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.F560S	0.3222	90.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.F560S (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S526L	0.46	50.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S526L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1001K	0.2791	43.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1001K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1128S	0.2111	90.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1128S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R130K	0.39	100.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R130K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P85S	0.6667	27.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P85S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T1066I	0.9	50.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T1066I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T715S	0.8409	44.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T715S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1101S	0.8214	28.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1101S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S373L	0.9091	44.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S373L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E744K	0.2872	188.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E744K (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.K889N	0.2574	101.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.K889N (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T796I	0.2689	212.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T796I (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P727L	0.3269	156.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.P727L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S904F	0.75	24.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S904F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.L485*	0.5469	64.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L485* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1859S	0.303	33.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P1859S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K1264E	0.3056	72.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K1264E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1792F	0.4074	81.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1792F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E272K	0.1714	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E272K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2067F	0.3714	35.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2067F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2695L	0.3136	118.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2695L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G2529S	0.2844	109.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G2529S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G2529D	0.2925	106.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G2529D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E626K	0.2388	67.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E626K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MK-06A-11D-A196-08	TCGA-EE-A2MK-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.Q202*	0.4	25.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.Q202* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1876K	0.45	80.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1876K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P740S	0.4301	93.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P740S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H223Y	0.5476	42.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H223Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P606S	0.7812	32.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P606S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Nonsense	p.W85*	0.2162	37.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.W85* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P606L	0.2237	76.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P606L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H1752Y	0.314	86.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H1752Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P3324L	0.2895	76.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P3324L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.H513Y	0.3023	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.H513Y (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E1214D	0.4286	42.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1214D (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P832S	0.4231	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P832S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2704F	0.1667	66.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2704F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3252F	0.3273	110.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3252F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Splice Site	p.X25_splice	0.3718	78.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.X25_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P747L	0.2281	171.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P747L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H334Y	0.3103	116.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H334Y (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MP-06A-11D-A197-08	TCGA-EE-A2MP-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1589C	0.2479	234.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1589C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.T1087I	0.3036	112.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T1087I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P606L	0.3596	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P606L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F1092L	0.56	125.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F1092L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L1598F	0.2778	126.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L1598F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A17Y-06A-11D-A196-08	TCGA-EE-A17Y-10B-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P555L	0.4203	69.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P555L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2307L	0.3846	26.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2307L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E402K	0.4531	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E402K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L35F	0.3434	99.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L35F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1547E	0.3217	115.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1547E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P493L	0.3913	69.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P493L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q3398H	0.303	66.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q3398H (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N113K	0.4388	139.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N113K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2107S	0.2759	58.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2107S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P375S	0.393	486.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P375S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2187L	0.4578	83.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2187L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.L269V	0.2297	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.L269V (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L2917F	0.4286	28.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L2917F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1749S	0.2596	366.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P1749S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R316K	0.4545	44.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R316K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A51E-06A-11D-A25O-08	TCGA-D3-A51E-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P985L	0.3173	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P985L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P1702L	0.3864	44.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P1702L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-XV-AAZW-01A-12D-A401-08	TCGA-XV-AAZW-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3333	102.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.P33S	0.3	100.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.P33S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3077	78.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5ER-01A-12D-A27K-08	TCGA-BF-A5ER-10A-01D-A27N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4194	93.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2696	115.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4138	87.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A268-06A-11D-A196-08	TCGA-GN-A268-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132L	0.375	48.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132L (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.225	80.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3952	124.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.E361K	0.2963	54.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.E361K (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3958	48.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Splice Site	p.X174_splice	0.3788	66.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.X174_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3833	120.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A3ES-06A-11D-A20D-08	TCGA-ER-A3ES-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132L	0.2593	81.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132L (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2526	95.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.5217	115.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.1786	112.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A42L-06A-11D-A24R-08	TCGA-ER-A42L-10A-01D-A24R-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4545	66.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2857	70.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.P33S	0.2206	68.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.P33S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.F1071S	0.3333	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.F1071S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.R249C	0.3734	158.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.R249C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P182S	0.6818	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P182S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P454S	0.2346	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P454S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P411S	0.2443	131.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P411S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P845S	0.252	123.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P845S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.F495I	0.3614	83.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.F495I (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P113S	0.339	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P113S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P90S	0.1667	42.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P90S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.R21L	0.5161	31.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.R21L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S835P	0.1868	91.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S835P (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.G190E	0.3158	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.G190E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S895F	0.4757	103.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S895F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.V917D	0.2963	27.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.V917D (Missense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.G304E	0.3143	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.G304E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.Q1056*	0.26	50.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.Q1056* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.X831_splice	0.5215	186.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.X831_splice (Splice Site)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P1101L	0.3373	169.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P1101L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L1170F	0.3226	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L1170F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.S296F	0.236	89.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.S296F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Nonsense	p.Q685*	0.3305	233.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.Q685* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.G345R	0.8	15.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.G345R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.A435V	0.5882	17.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.A435V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.I983S	0.3571	42.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.I983S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S644L	0.4685	111.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S644L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.A527V	0.5152	33.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.A527V (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A2JC-06A-11D-A19A-08	TCGA-D3-A2JC-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.X598_splice	0.3926	135.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.X598_splice (Splice Site)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L679F	0.2812	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L679F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.G162R	0.2347	98.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.G162R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P1238S	0.4112	107.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P1238S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P812S	0.4583	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P812S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P707S	0.4111	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P707S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.N118K	0.3514	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.N118K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P1246L	0.234	94.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P1246L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P90S	0.3939	33.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P90S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P1077S	0.3273	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P1077S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R160C	0.2529	87.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.R160C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S206L	0.3494	83.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S206L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.R249C	0.3846	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.R249C (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.F328S	0.3472	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.F328S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.R1097C	0.5	44.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.R1097C (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P683S	0.2673	101.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P683S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P222L	0.2222	99.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P222L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R773C	0.3889	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R773C (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.T1206A	0.3258	89.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.T1206A (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L177F	0.2347	196.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L177F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.S212F	0.2326	43.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.S212F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P1098L	0.7857	14.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P1098L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R1067Q	0.3767	146.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R1067Q (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S1306F	0.2143	308.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S1306F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.G193R	0.2151	93.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.G193R (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S987F	0.5	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S987F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.Q944*	0.5167	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q944* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.E1757K	0.2523	107.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.E1757K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.A12V	0.6226	53.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.A12V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P1264L	0.5714	35.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P1264L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P568L	0.3382	204.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P568L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-WE-A8ZO-06A-11D-A372-08	TCGA-WE-A8ZO-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P1675L	0.35	40.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P1675L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1398L	0.3676	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1398L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P961S	0.3122	189.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P961S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.I871L	0.3182	66.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.I871L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41B-01A-11D-A24R-08	TCGA-EB-A41B-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1313S	0.3115	183.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1313S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A41B-01A-11D-A24R-08	TCGA-EB-A41B-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P878S	0.4	35.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P878S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P878L	0.4	35.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P878L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.E340K	0.4863	183.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.E340K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A4F0-06A-11D-A24R-08	TCGA-FS-A4F0-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P629S	0.4581	179.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P629S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P545L	0.2689	119.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P545L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.S1798F	0.4444	27.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.S1798F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L796F	0.2195	41.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L796F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P585L	0.3015	262.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P585L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P768L	0.3796	108.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P768L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.M1326I	0.2558	43.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.M1326I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.T209I	0.3261	46.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.T209I (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.S1220T	0.338	142.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.S1220T (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.R908Q	0.1771	175.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.R908Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.D386N	0.6364	99.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.D386N (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P589S	0.2979	47.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P589S (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.H230Y	0.1875	64.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.H230Y (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R882W	0.362	163.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R882W (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-A3DN-01A-11D-A20D-08	TCGA-BF-A3DN-10A-01D-A20D-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.S575F	0.5636	55.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.S575F (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.E660K	0.2931	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.E660K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1005L	0.2857	112.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1005L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L1137F	0.2941	153.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L1137F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G614E	0.6562	32.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G614E (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site	p.X775_splice	0.4038	52.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.X775_splice (Splice Site)	0	SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S391F	0.3256	86.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S391F (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L596F	0.2525	99.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L596F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	ERBB2	Nonsense	p.Q156*	0.3721	86.0	0.0	0.0		Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	Ado-trasuzumab emtansine is an available targeted agent with activity against ERBB2 variants in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf																	ERBB2 p.Q156* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S327L	0.6486	37.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S327L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E219K	0.1733	75.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E219K (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.T946I	0.2727	55.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.T946I (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E320K	0.4815	27.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E320K (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site	p.X123_splice	0.4786	117.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.X123_splice (Splice Site)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S268L	0.2281	57.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S268L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.N488S	0.2906	117.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.N488S (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P408L	0.5481	104.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P408L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.T1069A	0.3855	83.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.T1069A (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G92R	0.2845	116.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G92R (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G105R	0.3452	84.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G105R (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P1013L	0.3902	41.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P1013L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H762Y	0.6071	56.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H762Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P555L	0.2436	78.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P555L (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.K1094I	0.4667	45.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.K1094I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H682Y	0.3099	71.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H682Y (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L14P	0.2941	17.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L14P (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P46L	0.4286	35.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P46L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Nonsense	p.Q61*	0.3321	1054.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61* (Nonsense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P179S	0.386	57.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P179S (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S490F	0.6106	113.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S490F (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R1068Q	0.3778	45.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R1068Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A97M-01A-11D-A38G-08	TCGA-EB-A97M-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.G166E	0.4901	151.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.G166E (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.V474M	0.3	40.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.V474M (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Nonsense	p.R326*	0.963	27.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R326* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.H1152Y	0.2623	122.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.H1152Y (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G230E	0.2069	29.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G230E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G230R	0.1724	29.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G230R (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1225S	0.2182	55.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1225S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GE-06A-11D-A196-08	TCGA-EE-A2GE-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1062Q	0.4194	62.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1062Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.N589D	0.3558	104.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N589D (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.P973S	0.3438	64.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.P973S (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.D530V	0.4219	64.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.D530V (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.K763E	0.3048	187.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.K763E (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Nonsense	p.G777*	0.3793	116.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.G777* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.H1408Y	0.2869	122.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.H1408Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.Q1301*	0.3789	161.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.Q1301* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.R580*	0.2581	93.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R580* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R876C	0.2895	38.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R876C (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.G338R	0.3983	118.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.G338R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.Q462*	0.25	68.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Q462* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.S307L	0.2967	209.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.S307L (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P284T	0.3086	175.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.P284T (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.H1228Y	0.2911	79.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.H1228Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P412L	0.1569	102.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P412L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.D758N	0.5369	244.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.D758N (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.P326S	0.5808	229.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.P326S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1096C	0.4314	153.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1096C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G371E	0.7333	105.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G371E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.V1184A	0.3788	66.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V1184A (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.D380V	0.32	25.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.D380V (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.D80N	0.1695	118.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.D80N (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19W-06A-41D-A23B-08	TCGA-ER-A19W-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.R680*	0.2676	71.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R680* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L1672M	0.8224	107.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L1672M (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.P314S	0.5714	154.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.P314S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JG-06A-11D-A196-08	TCGA-D3-A2JG-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R121C	0.3209	134.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R121C (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Nonsense	p.W112*	0.3626	91.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.W112* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.S457F	0.3333	69.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.S457F (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P313S	0.5888	107.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P313S (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.K1270Q	0.4507	71.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K1270Q (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.Q395*	0.7634	93.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Q395* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.E46K	0.2913	103.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.E46K (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Nonsense	p.Y553*	0.157	121.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y553* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P354S	0.248	125.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.P354S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G165E	0.3276	58.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G165E (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.E43K	0.717	53.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E43K (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A42K-06A-11D-A24R-08	TCGA-ER-A42K-10A-01D-A24R-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.L108P	0.9062	64.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L108P (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FS-A1ZD-06A-11D-A197-08	TCGA-FS-A1ZD-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G251V	0.9545	22.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G251V (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A17Z-06A-11D-A196-08	TCGA-EE-A17Z-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.M264R	0.4429	70.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.M264R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EB-A42Y-01A-12D-A24R-08	TCGA-EB-A42Y-10A-01D-A24R-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.L108F	0.71	100.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L108F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-BF-A5EP-01A-12D-A27K-08	TCGA-BF-A5EP-10A-01D-A27N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P246S	0.3855	83.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P246S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P246L	0.3793	87.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P246L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.C136R	0.7414	58.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.C136R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A3C6-06A-12D-A196-08	TCGA-D3-A3C6-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38S	0.3269	52.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38S	0.3333	36.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P89L	0.2857	21.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P89L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A2JC-06A-11D-A19A-08	TCGA-D3-A2JC-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38S	0.2826	46.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-HR-A2OH-06A-11D-A197-08	TCGA-HR-A2OH-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38L	0.2826	46.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-HR-A2OH-06A-11D-A197-08	TCGA-HR-A2OH-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.Y29S	0.6842	19.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y29S (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130L	0.6275	51.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.F257L	0.381	84.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.F257L (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D3-A8GD-06A-11D-A372-08	TCGA-D3-A8GD-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.Y177F	0.8909	55.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y177F (Missense)	1	SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.H272R	0.7	10.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.H272R (Missense)	1	SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Nonsense	p.K175*	0.2685	108.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.K175* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Nonsense	p.Q989*	0.3473	167.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.Q989* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Nonsense	p.W247*	0.2469	243.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.W247* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P776L	0.2843	102.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P776L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1321S	0.3243	74.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1321S (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P531L	0.3517	145.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P531L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P886S	0.2222	27.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P886S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2087R	0.3871	93.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2087R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2087E	0.3936	94.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2087E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R710C	0.2679	56.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R710C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G869S	0.3175	63.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G869S (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P798L	0.25	288.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P798L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1262C	0.4603	63.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1262C (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1321S	0.3617	94.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1321S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P2077S	0.4138	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P2077S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1747S	0.7531	81.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1747S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Nonsense	p.E765*	0.4509	224.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E765* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A6QZ-01A-12D-A32N-08	TCGA-EB-A6QZ-10B-01D-A32N-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X911_splice	0.2632	19.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X911_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-ER-A19B-06A-11D-A196-08	TCGA-ER-A19B-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P2077S	0.3333	141.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P2077S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T950I	0.3535	99.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T950I (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Nonsense	p.Q970*	0.3419	427.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.Q970* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E1051K	0.4444	99.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E1051K (Missense)	0	SKCM_SOMATICSNIPER	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1001F	0.3271	107.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S1001F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1588F	0.2727	66.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S1588F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R973W	0.2653	49.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R973W (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1190V	0.4844	64.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1190V (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K785R	0.3	40.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K785R (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1504L	0.1446	83.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1504L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P389L	0.3154	149.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P389L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.3378	74.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P680S	0.2941	34.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P680S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R847C	0.3443	427.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R847C (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P277S	0.3333	27.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P277S (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FD-06A-11D-A25O-08	TCGA-FS-A4FD-10B-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R841S	0.2593	27.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R841S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP8-01A-11D-A401-08	TCGA-BF-AAP8-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.Y244H	0.3291	632.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.Y244H (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G274S	0.2805	82.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G274S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K1461N	0.44	25.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K1461N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E780K	0.375	104.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E780K (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P265S	0.2907	86.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P265S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q120*	0.1806	72.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q120* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R978Q	0.4286	35.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R978Q (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E554G	0.3558	104.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E554G (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1135W	0.3529	17.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1135W (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.3828	128.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Splice Site	p.X242_splice	0.2907	86.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.X242_splice (Splice Site)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Nonsense	p.Q47*	0.3919	74.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.Q47* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.G423*	0.4856	208.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G423* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.S211G	0.3256	43.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.S211G (Missense)	0	SKCM_SOMATICSNIPER	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.C308*	0.2388	67.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.C308* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U9-06A-11D-A32N-08	TCGA-GN-A4U9-10B-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.N1540H	0.4375	48.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.N1540H (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1403G	0.2532	79.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1403G (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q120*	0.75	28.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q120* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E669K	0.3112	347.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E669K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.P615S	0.4268	157.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.P615S (Missense)	0	SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Nonsense	p.W582*	0.2658	489.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.W582* (Nonsense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.G423*	0.3587	223.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G423* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E882K	0.2857	21.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E882K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1418N	0.4894	47.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1418N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1468V	0.3404	94.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1468V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1180S	0.625	8.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1180S (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R469W	0.28	25.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R469W (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E861K	0.3939	33.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E861K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1344S	0.3793	29.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1344S (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R847C	0.5859	99.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R847C (Missense)	0	SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P270S	0.4286	105.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P270S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1424S	0.25	36.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1424S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.K793E	0.3177	639.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.K793E (Missense)	0	SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1468V	0.3182	44.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1468V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X1021_splice	0.4262	61.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X1021_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S317F	0.8571	14.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S317F (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.V656L	0.5938	32.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.V656L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R471K	0.2879	66.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R471K (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D629N	0.2705	122.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D629N (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S459L	0.2182	55.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S459L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.R243C	0.3051	59.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R243C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S235F	0.3881	67.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S235F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.L661M	0.3333	75.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.L661M (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.L1182F	0.2679	112.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.L1182F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Nonsense	p.Q739*	0.5758	33.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.Q739* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.T1018I	0.2609	23.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.T1018I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.R434W	0.5926	27.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R434W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.F7L	0.3929	28.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.F7L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Nonsense	p.R787*	0.9231	39.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R787* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.S463F	0.3054	167.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.S463F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P566L	0.4336	113.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P566L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P896S	0.2105	76.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P896S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P272S	0.2174	46.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P272S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.G415R	0.6429	14.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.G415R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.S575L	0.314	86.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.S575L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D648N	0.2222	45.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D648N (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Nonsense	p.Q610*	0.4054	37.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.Q610* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S1092F	0.2857	105.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S1092F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P1256S	0.2569	144.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P1256S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P269S	0.2742	62.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P269S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51E-06A-11D-A25O-08	TCGA-D3-A51E-10A-01D-A25O-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E247K	0.2714	70.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E247K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P168L	0.339	118.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P168L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G345S	0.2574	101.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G345S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G505D	0.2233	103.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G505D (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.P406L	0.2517	147.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.P406L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.S704L	0.3517	145.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S704L (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P2190L	0.338	71.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P2190L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K1-06A-21D-A372-08	TCGA-WE-A8K1-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.5544	294.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1354C	0.4128	109.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1354C (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L886F	0.253	83.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L886F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A2041T	0.4387	155.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A2041T (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.L262F	0.2938	160.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.L262F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.5733	75.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Y592H	0.3765	162.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y592H (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L716V	0.2596	104.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L716V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Splice Site	p.X1391_splice	0.45	20.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.X1391_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1395K	0.4423	52.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1395K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R210C	0.584	125.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R210C (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZT-06A-11D-A197-08	TCGA-FS-A1ZT-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R14Q	0.2193	114.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R14Q (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I829N	0.2067	150.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I829N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.H426L	0.2581	62.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.H426L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P133S	0.451	51.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P133S (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P432S	0.4706	34.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.P432S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP2-01A-11D-A401-08	TCGA-BF-AAP2-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.E241K	0.2652	132.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.E241K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GB-06A-11D-A197-08	TCGA-EE-A2GB-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P317S	0.4488	254.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P317S (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.V1047G	0.3779	172.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.V1047G (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1949W	0.6	150.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1949W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.H114Y	0.2358	123.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.H114Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.Y414F	0.2353	85.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y414F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S475F	0.3289	152.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S475F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.G137E	0.2883	111.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.G137E (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.G301W	0.4235	85.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.G301W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P2133L	0.5366	123.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P2133L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.A461T	0.6555	209.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.A461T (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P567L	0.3043	69.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P567L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Nonsense	p.R425*	0.5581	43.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R425* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P729L	0.4779	136.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P729L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S958L	0.5887	124.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S958L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1094H	0.3969	131.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1094H (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.L117F	0.3	190.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.L117F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P1724L	0.4821	56.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P1724L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P1452S	0.8649	74.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P1452S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P1392L	0.4538	130.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P1392L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A98T	0.2529	87.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A98T (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A26A-06A-11D-A19A-08	TCGA-GN-A26A-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P33L	0.3401	147.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.P33L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Nonsense	p.G330*	0.3664	131.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.G330* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.C563F	0.3057	157.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.C563F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1612K	0.595	242.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1612K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.Q510H	0.9527	338.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.Q510H (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F0-06A-11D-A24R-08	TCGA-FS-A4F0-10A-01D-A24R-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P284L	0.4194	62.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.P284L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.T1115S	0.4405	168.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.T1115S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZM-06A-11D-A372-08	TCGA-WE-A8ZM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R146Q	0.3295	88.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R146Q (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.S1178L	0.8987	158.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S1178L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1289W	0.2247	89.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1289W (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.H1586Y	0.3031	419.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.H1586Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1Z7-06A-11D-A197-08	TCGA-FS-A1Z7-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.L145F	0.6558	215.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.L145F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.L79S	0.2766	47.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.L79S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S203F	0.25	64.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S203F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.S284F	0.1714	70.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.S284F (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Y351N	0.2704	159.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y351N (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A3Z3-06A-11D-A23B-08	TCGA-D9-A3Z3-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.M1868R	0.2391	46.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.M1868R (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S132L	0.3086	243.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S132L (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.P267S	0.2935	92.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.P267S (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.H361Y	0.5192	52.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.H361Y (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.P204L	0.3582	134.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.P204L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1073L	0.5193	233.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1073L (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.M224I	0.359	39.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.M224I (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FB-06A-11D-A25O-08	TCGA-FS-A4FB-10B-01D-A25O-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1273C	0.5294	102.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1273C (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S26L	0.3011	93.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S26L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P1334L	0.375	48.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P1334L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.P271Q	0.3	70.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.P271Q (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E1175K	0.4262	61.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E1175K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S1251F	0.2571	35.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S1251F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.G544E	0.3333	108.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.G544E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R793Q	0.2895	38.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R793Q (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K292E	0.3012	83.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K292E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.L335F	0.2698	63.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.L335F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.3396	53.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.D816N	1.0	9.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.D816N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P606L	0.407	172.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P606L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.4783	46.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A42Y-01A-12D-A24R-08	TCGA-EB-A42Y-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S48F	0.3393	507.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S48F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R171W	0.871	31.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R171W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.5128	39.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41I	0.325	40.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41I (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.Q545*	0.3673	49.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.Q545* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3095	84.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EG-06A-12D-A32N-08	TCGA-D9-A6EG-10A-01D-A32N-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.V4F	0.2353	17.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.V4F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S33L	0.3077	13.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S33L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P714L	0.28	50.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P714L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.Q200*	0.3143	35.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q200* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R1347K	0.3671	79.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R1347K (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZO-06A-11D-A372-08	TCGA-WE-A8ZO-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41N	0.2787	61.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41N (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5SH-06A-11D-A30X-08	TCGA-EB-A5SH-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.L916F	0.3969	131.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.L916F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R818C	0.4176	182.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R818C (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.I749N	0.2547	106.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.I749N (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T595I	0.3529	170.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T595I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R808C	0.4364	110.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R808C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.S315F	0.25	36.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.S315F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GL-06A-11D-A196-08	TCGA-EE-A2GL-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P687S	0.2812	128.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P687S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P687L	0.2748	131.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P687L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.1778	45.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.2456	57.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.3182	22.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.C429G	0.4615	78.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.C429G (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q5-06A-11D-A196-08	TCGA-D3-A1Q5-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.2558	43.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E638K	1.0	14.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E638K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E656K	0.2963	27.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E656K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D390E	0.3929	56.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D390E (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6E9-06A-12D-A30X-08	TCGA-D9-A6E9-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L762P	0.2432	37.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L762P (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45C	0.3409	44.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45C (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S212F	0.3922	51.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S212F (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P2053A	0.363	303.0	0.0	0.0																									MTOR p.P2053A (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G169R	0.4151	106.0	0.0	0.0																									NTRK1 p.G169R (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A871T	0.4494	89.0	0.0	0.0																									PDGFRB p.A871T (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Nonsense	p.Q443*	0.4624	186.0	0.0	0.0																									PDGFRB p.Q443* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G355E	0.6279	86.0	0.0	0.0																									ESRP1 p.G355E (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6429	14.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R210Q	0.3525	139.0	0.0	0.0																									FGFR2 p.R210Q (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.W170*	0.3636	66.0	0.0	0.0																									NTRK3 p.W170* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.D654N	0.4783	23.0	0.0	0.0																									IL12RB1 p.D654N (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S531F	0.4531	64.0	0.0	0.0																									LIMK2 p.S531F (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L547F	0.5189	106.0	0.0	0.0																									MTOR p.L547F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D235N	0.4412	136.0	0.0	0.0																									RUNX1T1 p.D235N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E357K	0.3339	593.0	0.0	0.0																									ESRP1 p.E357K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5743	148.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P577S	0.3827	81.0	0.0	0.0																									NTRK3 p.P577S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H370N	0.2893	159.0	0.0	0.0																									NTRK3 p.H370N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y1625*	0.5106	94.0	0.0	0.0																									NF1 p.Y1625* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.2286	140.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P48L	0.2955	44.0	0.0	0.0																									TMPRSS2 p.P48L (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R439W	0.436	172.0	0.0	0.0																									PDGFRB p.R439W (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A97M-01A-11D-A38G-08	TCGA-EB-A97M-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.3047	128.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.2254	71.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F8-06A-11D-A25O-08	TCGA-FS-A4F8-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2136R	0.3025	119.0	0.0	0.0																									ROS1 p.G2136R (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G111R	0.4167	60.0	0.0	0.0																									ROS1 p.G111R (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D313N	0.2039	103.0	0.0	0.0																									RUNX1T1 p.D313N (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.375	48.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S129L	0.5455	55.0	0.0	0.0																									FGFR2 p.S129L (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.S359F	0.36	100.0	0.0	0.0																									NTRK3 p.S359F (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.G675R	0.3167	60.0	0.0	0.0																									NF1 p.G675R (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.T464S	0.3333	54.0	0.0	0.0																									TPX2 p.T464S (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S41L	0.2679	56.0	0.0	0.0																									LIMK2 p.S41L (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P233S	0.1471	68.0	0.0	0.0																									ESRP1 p.P233S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YE-06A-11D-A372-08	TCGA-FR-A8YE-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.F275L	0.4533	75.0	0.0	0.0																									CCNE1 p.F275L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A262-06A-11D-A196-08	TCGA-GN-A262-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2127F	0.6591	132.0	0.0	0.0																									MTOR p.S2127F (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1108S	0.5873	63.0	0.0	0.0																									ROS1 p.P1108S (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1007E	0.2414	58.0	0.0	0.0																									ROS1 p.G1007E (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1007R	0.2456	57.0	0.0	0.0																									ROS1 p.G1007R (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y491*	0.641	39.0	0.0	0.0																									NF1 p.Y491* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L492I	0.641	39.0	0.0	0.0																									NF1 p.L492I (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G800E	0.7727	44.0	0.0	0.0																									COL1A1 p.G800E (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G614E	0.75	20.0	0.0	0.0																									COL1A1 p.G614E (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1134L	0.2807	57.0	0.0	0.0																									BRD4 p.P1134L (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.D202N	0.6607	56.0	0.0	0.0																									TMPRSS2 p.D202N (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.L437F	0.3659	82.0	0.0	0.0																									NTRK1 p.L437F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.4643	28.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1392_splice	0.2414	87.0	0.0	0.0																									NF1 p.X1392_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A814V	0.2321	56.0	0.0	0.0																									COL1A1 p.A814V (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.E369K	0.5051	293.0	0.0	0.0																									MYC p.E369K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R579*	0.2258	31.0	0.0	0.0																									RB1 p.R579* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.R316C	0.2361	72.0	0.0	0.0																									LIMK2 p.R316C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1929S	0.4762	42.0	0.0	0.0																									ROS1 p.P1929S (Missense)		SKCM_SOMATICSNIPER	TCGA-HR-A5NC-01A-11D-A27K-08	TCGA-HR-A5NC-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G251S	0.16	75.0	0.0	0.0																									COL1A1 p.G251S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K1-06A-21D-A372-08	TCGA-WE-A8K1-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q237*	0.1667	96.0	0.0	0.0																									ROS1 p.Q237* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Y	0.4412	34.0	0.0	0.0																									CDKN2A p.H83Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P698L	0.2451	102.0	0.0	0.0																									NF1 p.P698L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.6522	23.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P366S	0.3333	63.0	0.0	0.0																									COL1A1 p.P366S (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1667S	0.2714	140.0	0.0	0.0																									NF1 p.P1667S (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K6-06A-11D-A372-08	TCGA-WE-A8K6-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R796C	0.2521	119.0	0.0	0.0																									COL1A1 p.R796C (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K6-06A-11D-A372-08	TCGA-WE-A8K6-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G594R	0.84	25.0	0.0	0.0																									RUNX1T1 p.G594R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1258*	0.8714	350.0	0.0	0.0																									NF1 p.W1258* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G281D	0.8799	458.0	0.0	0.0																									COL1A1 p.G281D (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G476R	0.3951	448.0	0.0	0.0																									ESRP1 p.G476R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1810F	0.6296	27.0	0.0	0.0																									ROS1 p.S1810F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.A264T	0.4615	13.0	0.0	0.0																									FGFR2 p.A264T (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1487S	0.4342	76.0	0.0	0.0																									NF1 p.P1487S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E31K	0.3158	19.0	0.0	0.0																									LIMK2 p.E31K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P612S	0.2174	69.0	0.0	0.0																									TACC3 p.P612S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T28I	0.259	166.0	0.0	0.0																									ROS1 p.T28I (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P596S	0.44	25.0	0.0	0.0																									RUNX1T1 p.P596S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.2403	129.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E711K	0.329	155.0	0.0	0.0																									FGFR2 p.E711K (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G178E	0.38	50.0	0.0	0.0																									NTRK3 p.G178E (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q684*	0.2812	96.0	0.0	0.0																									NF1 p.Q684* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1815*	0.2466	146.0	0.0	0.0																									NF1 p.Q1815* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P412S	0.2933	75.0	0.0	0.0																									COL1A1 p.P412S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S243F	0.2232	112.0	0.0	0.0																									KEAP1 p.S243F (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.A1245V	0.3333	30.0	0.0	0.0																									BRD4 p.A1245V (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P216S	0.2703	370.0	0.0	0.0																									BRD4 p.P216S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P351S	0.2414	145.0	0.0	0.0																									ERG p.P351S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	TMPRSS2	Splice Site	p.X80_splice	0.2281	57.0	0.0	0.0																									TMPRSS2 p.X80_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.P287S	0.3387	496.0	0.0	0.0																									CRKL p.P287S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N1834H	1.0	15.0	0.0	0.0																									ROS1 p.N1834H (Missense)		SKCM_SOMATICSNIPER	TCGA-3N-A9WB-06A-11D-A38G-08	TCGA-3N-A9WB-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.26	50.0	0.0	0.0																									RAF1 p.S257L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.P536S	0.4257	101.0	0.0	0.0																									MLH1 p.P536S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2177E	0.2927	41.0	0.0	0.0																									ROS1 p.G2177E (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1385F	0.4107	56.0	0.0	0.0																									ROS1 p.L1385F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.E489K	0.4062	96.0	0.0	0.0																									PMS2 p.E489K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P593L	0.375	16.0	0.0	0.0																									RUNX1T1 p.P593L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.R392C	0.5128	78.0	0.0	0.0																									ERG p.R392C (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1859K	0.2955	44.0	0.0	0.0																									ROS1 p.E1859K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1062K	0.4933	75.0	0.0	0.0																									ROS1 p.E1062K (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.6923	13.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G727E	0.3902	41.0	0.0	0.0																									NTRK3 p.G727E (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W336*	0.2679	56.0	0.0	0.0																									NF1 p.W336* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W336*	0.2679	56.0	0.0	0.0																									NF1 p.W336* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E2469*	0.4474	76.0	0.0	0.0																									NF1 p.E2469* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1179S	0.6531	49.0	0.0	0.0																									COL1A1 p.P1179S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L935Q	0.3077	13.0	0.0	0.0																									BRD4 p.L935Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83R	0.9126	103.0	0.0	0.0																									CDKN2A p.H83R (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A1X3-06A-11D-A197-08	TCGA-D9-A1X3-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24H	0.2623	61.0	0.0	0.0																									CDK4 p.R24H (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44R-06A-41D-A25O-08	TCGA-EB-A44R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1025R	0.4	60.0	0.0	0.0																									ROS1 p.G1025R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2580_splice	0.4458	166.0	0.0	0.0																									NF1 p.X2580_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2265K	0.3924	79.0	0.0	0.0																									ROS1 p.E2265K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V2125A	0.4087	208.0	0.0	0.0																									ROS1 p.V2125A (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1509K	0.475	40.0	0.0	0.0																									ROS1 p.E1509K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G316D	0.2881	59.0	0.0	0.0																									FGFR2 p.G316D (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.P367S	0.4231	52.0	0.0	0.0																									POLE2 p.P367S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S291F	0.3594	64.0	0.0	0.0																									LIMK2 p.S291F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.L1109*	0.575	40.0	0.0	0.0																									NF1 p.L1109* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.M1149V	0.2439	41.0	0.0	0.0																									NF1 p.M1149V (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1799K	0.4783	23.0	0.0	0.0																									MTOR p.E1799K (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R333H	0.1963	107.0	0.0	0.0																									RAF1 p.R333H (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S405F	0.4863	183.0	0.0	0.0																									MLH1 p.S405F (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D776N	0.2925	106.0	0.0	0.0																									PDGFRB p.D776N (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S79L	0.3488	43.0	0.0	0.0																									ROS1 p.S79L (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S83C	0.3684	76.0	0.0	0.0																									RUNX1T1 p.S83C (Missense)		SKCM_SOMATICSNIPER	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ESRP1	Nonsense	p.R264*	0.6774	248.0	0.0	0.0																									ESRP1 p.R264* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S10L	0.6667	9.0	0.0	0.0																									FLI1 p.S10L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E163K	0.1622	74.0	0.0	0.0																									FGFR2 p.E163K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JE-06A-11D-A20D-08	TCGA-EE-A3JE-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.7692	39.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H856Y	0.5667	30.0	0.0	0.0																									ROS1 p.H856Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R149H	0.4912	57.0	0.0	0.0																									RUNX1T1 p.R149H (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S141L	0.2105	57.0	0.0	0.0																									RUNX1T1 p.S141L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W784*	0.1944	36.0	0.0	0.0																									NF1 p.W784* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.H133Y	0.45	80.0	0.0	0.0																									EML4 p.H133Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S67F	0.2941	51.0	0.0	0.0																									MYC p.S67F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.P295S	0.7692	65.0	0.0	0.0																									NTRK2 p.P295S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.N155S	0.3529	102.0	0.0	0.0																									TMPRSS2 p.N155S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	LIMK2	Nonsense	p.R364*	0.4	35.0	0.0	0.0																									LIMK2 p.R364* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-BF-A3DM-01A-11D-A20D-08	TCGA-BF-A3DM-10A-02D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2143_splice	0.575	40.0	0.0	0.0																									NF1 p.X2143_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-BF-A1PZ-01A-11D-A19A-08	TCGA-BF-A1PZ-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G192E	0.3439	157.0	0.0	0.0																									ROS1 p.G192E (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G192R	0.9333	60.0	0.0	0.0																									ROS1 p.G192R (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q684*	0.3906	64.0	0.0	0.0																									NF1 p.Q684* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1599F	0.4889	90.0	0.0	0.0																									NF1 p.S1599F (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.L536V	0.5645	62.0	0.0	0.0																									LIMK2 p.L536V (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E810K	0.2261	115.0	0.0	0.0																									NTRK3 p.E810K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.N251K	0.1856	167.0	0.0	0.0																									AURKB p.N251K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S1641F	0.2826	138.0	0.0	0.0																									MTOR p.S1641F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.3284	134.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.9111	45.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.V648G	0.536	125.0	0.0	0.0																									EML4 p.V648G (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L376F	0.2036	997.0	0.0	0.0																									ESRP1 p.L376F (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.L765P	0.6667	51.0	0.0	0.0																									COL1A1 p.L765P (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.R316C	0.52	75.0	0.0	0.0																									LIMK2 p.R316C (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.K178R	0.6494	231.0	0.0	0.0																									PMS2 p.K178R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Splice Site	p.X42_splice	0.4	20.0	0.0	0.0																									IL12RB1 p.X42_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G661E	0.4474	76.0	0.0	0.0																									NTRK1 p.G661E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.4752	101.0	0.0	0.0																									RAF1 p.S257L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.M796I	0.3718	78.0	0.0	0.0																									NTRK2 p.M796I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.Y49F	0.2769	65.0	0.0	0.0																									NF1 p.Y49F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.D605V	0.4403	159.0	0.0	0.0																									BRD4 p.D605V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I1268T	0.2653	49.0	0.0	0.0																									ROS1 p.I1268T (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S259F	0.2778	108.0	0.0	0.0																									RAF1 p.S259F (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.R87C	0.1905	105.0	0.0	0.0																									CCND3 p.R87C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GN-06A-11D-A372-08	TCGA-D3-A8GN-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P807S	0.3271	107.0	0.0	0.0																									COL1A1 p.P807S (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.G786E	0.5405	74.0	0.0	0.0																									EML4 p.G786E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.D2077E	0.3043	69.0	0.0	0.0																									MTOR p.D2077E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.P484S	0.2273	44.0	0.0	0.0																									SLC45A3 p.P484S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.A20V	0.3864	88.0	0.0	0.0																									RAF1 p.A20V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1092N	0.375	80.0	0.0	0.0																									ROS1 p.S1092N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1006K	0.2029	69.0	0.0	0.0																									ROS1 p.E1006K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.H437P	0.2821	117.0	0.0	0.0																									POT1 p.H437P (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R243Q	0.2532	154.0	0.0	0.0																									RUNX1T1 p.R243Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.5215	303.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2239*	0.4667	90.0	0.0	0.0																									NF1 p.Q2239* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P978S	0.54	50.0	0.0	0.0																									COL1A1 p.P978S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.D144N	0.5593	59.0	0.0	0.0																									TMPRSS2 p.D144N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R702C	0.2273	154.0	0.0	0.0																									NTRK1 p.R702C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G1016E	0.3304	112.0	0.0	0.0																									COL1A1 p.G1016E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.6033	121.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.S523L	0.3017	179.0	0.0	0.0																									POT1 p.S523L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JA-06A-11D-A196-08	TCGA-D3-A2JA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.7931	29.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P307L	0.3307	127.0	0.0	0.0																									BRD4 p.P307L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.L604*	0.3273	55.0	0.0	0.0																									NF1 p.L604* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G728E	0.3852	122.0	0.0	0.0																									COL1A1 p.G728E (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.L102F	0.3276	58.0	0.0	0.0																									SLC45A3 p.L102F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S981F	0.4667	75.0	0.0	0.0																									MTOR p.S981F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.M378K	0.5758	33.0	0.0	0.0																									FLI1 p.M378K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S390F	0.3077	39.0	0.0	0.0																									FLI1 p.S390F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q853*	0.7037	27.0	0.0	0.0																									NF1 p.Q853* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.R665K	0.3053	95.0	0.0	0.0																									EML4 p.R665K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.P156L	0.3504	137.0	0.0	0.0																									CRKL p.P156L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P458S	0.3803	71.0	0.0	0.0																									PDGFRB p.P458S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P852S	0.3435	131.0	0.0	0.0																									COL1A1 p.P852S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1278L	0.2394	71.0	0.0	0.0																									COL1A1 p.P1278L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A265-06A-21D-A197-08	TCGA-GN-A265-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S486T	0.2766	188.0	0.0	0.0																									MLH1 p.S486T (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S486Y	0.2796	186.0	0.0	0.0																									MLH1 p.S486Y (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q2216*	0.2706	85.0	0.0	0.0																									ROS1 p.Q2216* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1642K	0.3371	89.0	0.0	0.0																									ROS1 p.E1642K (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.V306L	0.2195	41.0	0.0	0.0																									PMS2 p.V306L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S164F	0.2733	150.0	0.0	0.0																									PMS2 p.S164F (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.3265	49.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22Q	0.5395	76.0	0.0	0.0																									CDK4 p.K22Q (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P243L	0.2367	169.0	0.0	0.0																									CCNE1 p.P243L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1026Q	0.4429	70.0	0.0	0.0																									COL1A1 p.R1026Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MK-06A-11D-A196-08	TCGA-EE-A2MK-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.R793*	0.5938	32.0	0.0	0.0																									NTRK3 p.R793* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.E83K	0.5082	61.0	0.0	0.0																									NTRK1 p.E83K (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.V2096M	0.9062	96.0	0.0	0.0																									NF1 p.V2096M (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R391S	0.6528	72.0	0.0	0.0																									RAF1 p.R391S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E352K	0.2208	77.0	0.0	0.0																									RUNX1T1 p.E352K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G364E	0.4286	77.0	0.0	0.0																									FGFR2 p.G364E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S833F	0.6471	17.0	0.0	0.0																									NF1 p.S833F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S544F	0.375	48.0	0.0	0.0																									IL12RB1 p.S544F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.G232E	0.3636	55.0	0.0	0.0																									ERG p.G232E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I594N	0.2043	93.0	0.0	0.0																									ROS1 p.I594N (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P423S	0.2252	111.0	0.0	0.0																									FGFR2 p.P423S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.A525T	0.2222	27.0	0.0	0.0																									RB1 p.A525T (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P225S	0.3962	53.0	0.0	0.0																									MTOR p.P225S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G623E	0.4848	66.0	0.0	0.0																									NTRK3 p.G623E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.M2264I	0.3385	65.0	0.0	0.0																									ROS1 p.M2264I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L862F	0.3077	65.0	0.0	0.0																									ROS1 p.L862F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.2441	127.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4857	105.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.W771*	0.65	160.0	0.0	0.0																									NTRK3 p.W771* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S249*	0.5506	89.0	0.0	0.0																									RB1 p.S249* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E819K	0.8133	75.0	0.0	0.0																									NTRK3 p.E819K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.26	50.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MG-06A-11D-A197-08	TCGA-EE-A2MG-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2420V	0.4	65.0	0.0	0.0																									MTOR p.A2420V (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.N440S	0.2956	203.0	0.0	0.0																									NTRK1 p.N440S (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2296K	0.2644	87.0	0.0	0.0																									ROS1 p.E2296K (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.A439T	0.4688	32.0	0.0	0.0																									ERG p.A439T (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP6-01A-11D-A401-08	TCGA-BF-AAP6-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1117D	0.7143	28.0	0.0	0.0																									ROS1 p.G1117D (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P470L	0.2044	137.0	0.0	0.0																									PMS2 p.P470L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S225L	0.5	72.0	0.0	0.0																									RUNX1T1 p.S225L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.8276	29.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.A375S	0.4308	65.0	0.0	0.0																									ERG p.A375S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2237E	0.6081	74.0	0.0	0.0																									ROS1 p.G2237E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.3171	41.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R210Q	0.381	105.0	0.0	0.0																									FGFR2 p.R210Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R116W	0.3364	217.0	0.0	0.0																									NTRK3 p.R116W (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Q2295H	0.7097	62.0	0.0	0.0																									ROS1 p.Q2295H (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.L79F	0.3025	119.0	0.0	0.0																									FGFR2 p.L79F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D235N	0.2373	118.0	0.0	0.0																									RUNX1T1 p.D235N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.A18T	0.2125	80.0	0.0	0.0																									CD274 p.A18T (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.K261E	0.53	100.0	0.0	0.0																									NTRK1 p.K261E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.R151C	0.3182	176.0	0.0	0.0																									PMS2 p.R151C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G288S	0.2456	57.0	0.0	0.0																									RUNX1T1 p.G288S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.5926	54.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.L87P	0.1649	97.0	0.0	0.0																									FGFR2 p.L87P (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2239*	0.5904	83.0	0.0	0.0																									NF1 p.Q2239* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G997S	0.434	53.0	0.0	0.0																									PDGFRB p.G997S (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4FD-06A-11D-A25O-08	TCGA-FS-A4FD-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L570F	0.5246	61.0	0.0	0.0																									MTOR p.L570F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.N62S	0.2121	33.0	0.0	0.0																									TMPRSS2 p.N62S (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A9SD-06A-11D-A401-08	TCGA-GN-A9SD-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q282*	0.25	40.0	0.0	0.0																									NF1 p.Q282* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1070*	0.2308	26.0	0.0	0.0																									NF1 p.Q1070* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R625Q	0.3019	159.0	0.0	0.0																									FGFR2 p.R625Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R251Q	0.4062	32.0	0.0	0.0																									FGFR2 p.R251Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V438I	0.5682	44.0	0.0	0.0																									ROS1 p.V438I (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S569F	0.5	34.0	0.0	0.0																									RUNX1T1 p.S569F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P420L	0.359	78.0	0.0	0.0																									ESRP1 p.P420L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P417L	0.2222	45.0	0.0	0.0																									NTRK3 p.P417L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.K289*	0.5161	31.0	0.0	0.0																									RB1 p.K289* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q846*	0.2553	47.0	0.0	0.0																									RB1 p.Q846* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P145L	0.1912	68.0	0.0	0.0																									EML4 p.P145L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1614S	0.2708	48.0	0.0	0.0																									ROS1 p.P1614S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1607L	0.561	41.0	0.0	0.0																									ROS1 p.P1607L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Q	0.3148	54.0	0.0	0.0																									CDKN2A p.H83Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D700N	0.5	16.0	0.0	0.0																									NTRK2 p.D700N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E163K	0.3103	58.0	0.0	0.0																									FGFR2 p.E163K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.4167	96.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2604F	0.5267	131.0	0.0	0.0																									NF1 p.L2604F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.H409Y	0.2931	58.0	0.0	0.0																									ERG p.H409Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E59Q	0.549	51.0	0.0	0.0																									NTRK2 p.E59Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S706F	0.2083	72.0	0.0	0.0																									BRD4 p.S706F (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.3458	107.0	0.0	0.0																									RAF1 p.S257L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R692C	0.4091	66.0	0.0	0.0																									NTRK1 p.R692C (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P2613L	0.2031	128.0	0.0	0.0																									NF1 p.P2613L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G194D	0.3333	81.0	0.0	0.0																									COL1A1 p.G194D (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P313L	0.2826	138.0	0.0	0.0																									ERG p.P313L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.P200L	0.3962	53.0	0.0	0.0																									POLE2 p.P200L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X69_splice	0.2656	64.0	0.0	0.0																									NF1 p.X69_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L274F	0.4889	45.0	0.0	0.0																									NF1 p.L274F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.T1419I	0.5472	53.0	0.0	0.0																									COL1A1 p.T1419I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3C6-06A-12D-A196-08	TCGA-D3-A3C6-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.N115H	0.2681	138.0	0.0	0.0																									RAF1 p.N115H (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.M667I	0.2063	63.0	0.0	0.0																									NTRK3 p.M667I (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P271L	0.2833	120.0	0.0	0.0																									CCNE1 p.P271L (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.N161K	0.4474	38.0	0.0	0.0																									RAF1 p.N161K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q257*	0.7436	39.0	0.0	0.0																									RB1 p.Q257* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1009S	0.4286	84.0	0.0	0.0																									COL1A1 p.P1009S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1083K	0.2571	70.0	0.0	0.0																									ROS1 p.E1083K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P523S	0.3716	183.0	0.0	0.0																									COL1A1 p.P523S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R1098W	0.3019	53.0	0.0	0.0																									PDGFRB p.R1098W (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.H642Y	0.1809	94.0	0.0	0.0																									MTOR p.H642Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.I144M	0.2333	120.0	0.0	0.0																									PMS2 p.I144M (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.R377C	0.2373	118.0	0.0	0.0																									ERG p.R377C (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.S195F	0.2826	92.0	0.0	0.0																									CRKL p.S195F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.R421G	0.2903	93.0	0.0	0.0																									PMS2 p.R421G (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.M2264I	0.35	60.0	0.0	0.0																									ROS1 p.M2264I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.P24S	0.398	98.0	0.0	0.0																									CD274 p.P24S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T370I	0.4576	59.0	0.0	0.0																									FGFR2 p.T370I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E1395K	0.375	64.0	0.0	0.0																									COL1A1 p.E1395K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P15L	0.2034	118.0	0.0	0.0																									BRD4 p.P15L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1997*	0.3667	90.0	0.0	0.0																									NF1 p.W1997* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A82B-01A-11D-A34U-08	TCGA-EB-A82B-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y2285*	0.2	125.0	0.0	0.0																									NF1 p.Y2285* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A82B-01A-11D-A34U-08	TCGA-EB-A82B-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.8396	106.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A185-06A-11D-A196-08	TCGA-EE-A185-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R2152C	0.3277	119.0	0.0	0.0																									MTOR p.R2152C (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R1616C	0.2558	86.0	0.0	0.0																									MTOR p.R1616C (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.E92K	0.3191	47.0	0.0	0.0																									NTRK1 p.E92K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R245W	0.3056	36.0	0.0	0.0																									SLC45A3 p.R245W (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.P87L	0.2933	75.0	0.0	0.0																									SLC45A3 p.P87L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S368L	0.3821	123.0	0.0	0.0																									MLH1 p.S368L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S1041F	0.2386	88.0	0.0	0.0																									PDGFRB p.S1041F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.V810M	0.2319	69.0	0.0	0.0																									PDGFRB p.V810M (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G687R	0.2717	92.0	0.0	0.0																									PDGFRB p.G687R (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2308K	0.4462	65.0	0.0	0.0																									ROS1 p.E2308K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1180T	0.434	106.0	0.0	0.0																									ROS1 p.A1180T (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H989Y	0.3562	73.0	0.0	0.0																									ROS1 p.H989Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.H552R	0.291	354.0	0.0	0.0																									PMS2 p.H552R (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E349K	0.2834	187.0	0.0	0.0																									RUNX1T1 p.E349K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S237L	0.2421	95.0	0.0	0.0																									ESRP1 p.S237L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R329C	0.209	67.0	0.0	0.0																									ESRP1 p.R329C (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.P59L	0.1731	52.0	0.0	0.0																									MYC p.P59L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P775L	0.3158	228.0	0.0	0.0																									FGFR2 p.P775L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E718K	0.2708	192.0	0.0	0.0																									FGFR2 p.E718K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E596K	0.2891	339.0	0.0	0.0																									FGFR2 p.E596K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.V311I	0.3333	99.0	0.0	0.0																									FGFR2 p.V311I (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.E173K	0.2596	208.0	0.0	0.0																									FLI1 p.E173K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.D209N	0.2756	156.0	0.0	0.0																									FLI1 p.D209N (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R257Q	0.25	28.0	0.0	0.0																									FLI1 p.R257Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.E323K	0.2955	44.0	0.0	0.0																									FLI1 p.E323K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R735C	0.3977	88.0	0.0	0.0																									NTRK3 p.R735C (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.L152F	0.2371	97.0	0.0	0.0																									NTRK3 p.L152F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q347*	0.378	127.0	0.0	0.0																									NF1 p.Q347* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E1238*	0.3902	246.0	0.0	0.0																									NF1 p.E1238* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P829L	0.3282	131.0	0.0	0.0																									COL1A1 p.P829L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.D1346E	0.2273	132.0	0.0	0.0																									BRD4 p.D1346E (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S717F	0.1786	56.0	0.0	0.0																									BRD4 p.S717F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S194F	0.2674	288.0	0.0	0.0																									BRD4 p.S194F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.E207K	0.3556	135.0	0.0	0.0																									IL12RB1 p.E207K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P291L	0.3393	112.0	0.0	0.0																									TPX2 p.P291L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R337Q	0.3072	153.0	0.0	0.0																									TPX2 p.R337Q (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P423H	0.2619	168.0	0.0	0.0																									TPX2 p.P423H (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P419L	0.2397	121.0	0.0	0.0																									ERG p.P419L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.S80N	0.2881	59.0	0.0	0.0																									ERG p.S80N (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.S61F	0.2097	62.0	0.0	0.0																									TMPRSS2 p.S61F (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P618S	0.4706	17.0	0.0	0.0																									EWSR1 p.P618S (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.G50R	0.2558	43.0	0.0	0.0																									PDGFB p.G50R (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TACC3	Nonsense	p.Q808*	0.2308	65.0	0.0	0.0																									TACC3 p.Q808* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R556*	0.7368	57.0	0.0	0.0																									RB1 p.R556* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A267-06A-21D-A196-08	TCGA-GN-A267-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A598T	0.1905	42.0	0.0	0.0																									TACC3 p.A598T (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E63K	0.2105	38.0	0.0	0.0																									PDGFRB p.E63K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.V292A	0.2	85.0	0.0	0.0																									FIP1L1 p.V292A (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.2034	118.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R191Q	0.4113	124.0	0.0	0.0																									PDGFB p.R191Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E836K	0.4419	43.0	0.0	0.0																									PDGFRB p.E836K (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S413F	0.3889	180.0	0.0	0.0																									RUNX1T1 p.S413F (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N65S	0.5172	29.0	0.0	0.0																									ROS1 p.N65S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.4897	194.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.P250H	0.28	50.0	0.0	0.0																									CDK4 p.P250H (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R735C	0.4091	22.0	0.0	0.0																									NTRK3 p.R735C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G517R	0.1707	82.0	0.0	0.0																									NTRK1 p.G517R (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.P425S	0.3214	56.0	0.0	0.0																									FIP1L1 p.P425S (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A452P	0.2381	42.0	0.0	0.0																									RUNX1T1 p.A452P (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E1395K	0.3607	61.0	0.0	0.0																									COL1A1 p.E1395K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1030S	0.4362	94.0	0.0	0.0																									COL1A1 p.P1030S (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.S222F	0.2769	65.0	0.0	0.0																									ERG p.S222F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E527K	0.4167	48.0	0.0	0.0																									ROS1 p.E527K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.T20I	0.2545	55.0	0.0	0.0																									FGFR1 p.T20I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S146L	0.2963	54.0	0.0	0.0																									MYC p.S146L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G356E	0.3125	128.0	0.0	0.0																									NTRK3 p.G356E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.287	108.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.5338	133.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZR-06A-21D-A197-08	TCGA-FS-A1ZR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2241K	0.32	25.0	0.0	0.0																									ROS1 p.E2241K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1154S	0.6	20.0	0.0	0.0																									ROS1 p.P1154S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E444K	0.2554	184.0	0.0	0.0																									RUNX1T1 p.E444K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.S35F	0.3922	51.0	0.0	0.0																									NTRK2 p.S35F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G227R	0.2787	61.0	0.0	0.0																									FGFR2 p.G227R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.H46Y	1.0	9.0	0.0	0.0																									FLI1 p.H46Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.S359F	0.2743	175.0	0.0	0.0																									NTRK3 p.S359F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S141F	0.2911	79.0	0.0	0.0																									LIMK2 p.S141F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1006A	0.4928	69.0	0.0	0.0																									ROS1 p.E1006A (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G325D	0.3778	45.0	0.0	0.0																									IL12RB1 p.G325D (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5221	113.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A26A-06A-11D-A19A-08	TCGA-GN-A26A-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P426L	0.2029	69.0	0.0	0.0																									FLI1 p.P426L (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E242K	0.449	49.0	0.0	0.0																									NTRK2 p.E242K (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.Q773*	0.2683	82.0	0.0	0.0																									NTRK3 p.Q773* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R2517*	0.4848	33.0	0.0	0.0																									NF1 p.R2517* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1210L	0.2449	49.0	0.0	0.0																									BRD4 p.P1210L (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S469F	0.3681	144.0	0.0	0.0																									IL12RB1 p.S469F (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P2049L	0.29	100.0	0.0	0.0																									ROS1 p.P2049L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1282S	0.375	32.0	0.0	0.0																									ROS1 p.P1282S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.Q220H	0.2353	85.0	0.0	0.0																									ERG p.Q220H (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H359Y	0.4479	163.0	0.0	0.0																									RUNX1T1 p.H359Y (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.A102V	0.9024	41.0	0.0	0.0																									CDKN2A p.A102V (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.58	50.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-ER-A19L-06A-12D-A197-08	TCGA-ER-A19L-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N2268T	0.5085	59.0	0.0	0.0																									ROS1 p.N2268T (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.E88K	0.5918	49.0	0.0	0.0																									CDKN2A p.E88K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.S539L	0.3724	196.0	0.0	0.0																									TPX2 p.S539L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A636V	0.4118	34.0	0.0	0.0																									NTRK1 p.A636V (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G728E	0.4353	85.0	0.0	0.0																									COL1A1 p.G728E (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1908I	0.24	25.0	0.0	0.0																									MTOR p.T1908I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1206F	0.7931	58.0	0.0	0.0																									ROS1 p.L1206F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P446S	0.3684	19.0	0.0	0.0																									ERG p.P446S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.L461P	0.5918	49.0	0.0	0.0																									RB1 p.L461P (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1Z0-06A-11D-A197-08	TCGA-FS-A1Z0-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.K419E	0.3061	49.0	0.0	0.0																									FGFR1 p.K419E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR1	Nonsense	p.Q309*	0.3371	89.0	0.0	0.0																									FGFR1 p.Q309* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R316*	0.3358	137.0	0.0	0.0																									RUNX1T1 p.R316* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S150L	0.3221	534.0	0.0	0.0																									ESRP1 p.S150L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.D366E	0.3218	432.0	0.0	0.0																									ESRP1 p.D366E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E828K	0.2381	84.0	0.0	0.0																									COL1A1 p.E828K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.P130L	0.2041	49.0	0.0	0.0																									KEAP1 p.P130L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2J7-06A-11D-A196-08	TCGA-D3-A2J7-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D584N	0.3521	71.0	0.0	0.0																									NTRK2 p.D584N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Q559L	0.2373	59.0	0.0	0.0																									RUNX1T1 p.Q559L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.4685	572.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S168F	0.2174	138.0	0.0	0.0																									LIMK2 p.S168F (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G733R	0.2923	65.0	0.0	0.0																									ROS1 p.G733R (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.H647Y	0.2444	135.0	0.0	0.0																									NF1 p.H647Y (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L844F	0.6579	38.0	0.0	0.0																									NF1 p.L844F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E778K	0.2368	114.0	0.0	0.0																									NTRK3 p.E778K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	FIP1L1	Nonsense	p.E22*	0.4211	19.0	0.0	0.0																									FIP1L1 p.E22* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Splice Site	p.X456_splice	0.3333	99.0	0.0	0.0																									PDGFRB p.X456_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I468L	0.8571	14.0	0.0	0.0																									ROS1 p.I468L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D347N	0.4355	62.0	0.0	0.0																									RUNX1T1 p.D347N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.M722I	0.4068	59.0	0.0	0.0																									FGFR2 p.M722I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P931L	0.5517	29.0	0.0	0.0																									NF1 p.P931L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.N1254S	0.7375	160.0	0.0	0.0																									COL1A1 p.N1254S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1933K	0.5625	16.0	0.0	0.0																									ROS1 p.E1933K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P708S	0.3116	215.0	0.0	0.0																									FGFR2 p.P708S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.A611V	0.2968	603.0	0.0	0.0																									FGFR2 p.A611V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P2675S	0.2584	89.0	0.0	0.0																									NF1 p.P2675S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1274H	0.4857	140.0	0.0	0.0																									NF1 p.L1274H (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1Z3-06A-11D-A197-08	TCGA-FS-A1Z3-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.2418	91.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.S673A	0.45	20.0	0.0	0.0																									COL1A1 p.S673A (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.H264Y	0.497	169.0	0.0	0.0																									RAF1 p.H264Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F0-06A-11D-A24R-08	TCGA-FS-A4F0-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.T340I	0.5152	33.0	0.0	0.0																									NTRK1 p.T340I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.5714	84.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24L	0.75	44.0	0.0	0.0																									CDK4 p.R24L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.G442R	0.5968	124.0	0.0	0.0																									TMPRSS2 p.G442R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.G708E	0.2872	94.0	0.0	0.0																									EML4 p.G708E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.P373S	0.6364	33.0	0.0	0.0																									FIP1L1 p.P373S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R863W	0.7714	35.0	0.0	0.0																									ROS1 p.R863W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S192L	0.4559	68.0	0.0	0.0																									MYC p.S192L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L929P	0.5517	116.0	0.0	0.0																									NF1 p.L929P (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.P342L	0.2982	114.0	0.0	0.0																									IL12RB1 p.P342L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.M587I	0.5909	44.0	0.0	0.0																									NTRK1 p.M587I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R685C	0.6585	41.0	0.0	0.0																									PDGFRB p.R685C (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1942W	0.2836	67.0	0.0	0.0																									ROS1 p.R1942W (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P466L	0.4041	146.0	0.0	0.0																									FGFR1 p.P466L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D398N	0.3893	149.0	0.0	0.0																									RUNX1T1 p.D398N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E50K	0.5283	53.0	0.0	0.0																									ESRP1 p.E50K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.S469F	0.2742	62.0	0.0	0.0																									NTRK2 p.S469F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E768K	0.5703	128.0	0.0	0.0																									FGFR2 p.E768K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R330Q	0.2245	49.0	0.0	0.0																									FGFR2 p.R330Q (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G76R	0.1875	96.0	0.0	0.0																									FGFR2 p.G76R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E318K	0.5745	47.0	0.0	0.0																									NTRK3 p.E318K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q129*	0.7209	43.0	0.0	0.0																									NF1 p.Q129* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G409E	0.3235	136.0	0.0	0.0																									IL12RB1 p.G409E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S168F	0.6548	168.0	0.0	0.0																									LIMK2 p.S168F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.T660I	0.5451	233.0	0.0	0.0																									ESRP1 p.T660I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D584N	0.4717	106.0	0.0	0.0																									NTRK3 p.D584N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1539S	0.4333	60.0	0.0	0.0																									ROS1 p.P1539S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A746V	0.3776	98.0	0.0	0.0																									ROS1 p.A746V (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R625Q	0.488	125.0	0.0	0.0																									FGFR2 p.R625Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.3901	141.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2539_splice	0.4324	37.0	0.0	0.0																									NF1 p.X2539_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.3303	218.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P81L	0.6281	121.0	0.0	0.0																									CDKN2A p.P81L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P375L	0.2987	77.0	0.0	0.0																									BRD4 p.P375L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.W1817*	0.3261	46.0	0.0	0.0																									ROS1 p.W1817* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S283F	0.3913	23.0	0.0	0.0																									LIMK2 p.S283F (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.D231N	0.1786	56.0	0.0	0.0																									MDM2 p.D231N (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP4-01A-11D-A401-08	TCGA-BF-AAP4-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.E1458K	0.4146	82.0	0.0	0.0																									NF1 p.E1458K (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP4-01A-11D-A401-08	TCGA-BF-AAP4-10A-01D-A401-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S210F	0.1633	49.0	0.0	0.0																									TACC3 p.S210F (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1943K	0.1977	86.0	0.0	0.0																									ROS1 p.E1943K (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S105F	0.1579	95.0	0.0	0.0																									RUNX1T1 p.S105F (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.S286F	0.275	40.0	0.0	0.0																									EWSR1 p.S286F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P305L	0.45	40.0	0.0	0.0																									TMPRSS2 p.P305L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44Q-06A-11D-A25O-08	TCGA-EB-A44Q-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P456L	0.3514	37.0	0.0	0.0																									TACC3 p.P456L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GJ-06A-11D-A372-08	TCGA-D3-A8GJ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1952*	0.7321	56.0	0.0	0.0																									NF1 p.W1952* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-A8ZM-06A-11D-A372-08	TCGA-WE-A8ZM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.T434M	0.228	250.0	0.0	0.0																									NTRK1 p.T434M (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P418L	0.205	278.0	0.0	0.0																									RUNX1T1 p.P418L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D444H	0.3716	148.0	0.0	0.0																									COL1A1 p.D444H (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24C	0.1809	94.0	0.0	0.0																									CDK4 p.R24C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19W-06A-41D-A23B-08	TCGA-ER-A19W-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L47F	0.3333	33.0	0.0	0.0																									ROS1 p.L47F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2298K	0.6552	29.0	0.0	0.0																									ROS1 p.E2298K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E387K	0.3663	101.0	0.0	0.0																									RUNX1T1 p.E387K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T2045M	0.2826	46.0	0.0	0.0																									ROS1 p.T2045M (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.H162Y	0.45	80.0	0.0	0.0																									CCNE1 p.H162Y (Missense)		SKCM_SOMATICSNIPER	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.D616N	0.2676	71.0	0.0	0.0																									NTRK1 p.D616N (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y6-01A-21D-A23B-08	TCGA-EB-A3Y6-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.Q168R	0.3333	57.0	0.0	0.0																									CDKN2C p.Q168R (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E431K	0.3829	175.0	0.0	0.0																									PDGFRB p.E431K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.E36K	0.7292	96.0	0.0	0.0																									CCND1 p.E36K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q282*	0.3226	31.0	0.0	0.0																									NF1 p.Q282* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W696*	0.2771	83.0	0.0	0.0																									NF1 p.W696* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.F294S	0.392	176.0	0.0	0.0																									CCNE1 p.F294S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.E120K	0.7679	56.0	0.0	0.0																									CDKN2C p.E120K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1705L	0.4023	87.0	0.0	0.0																									ROS1 p.S1705L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S941F	0.2857	42.0	0.0	0.0																									ROS1 p.S941F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L320F	0.2553	47.0	0.0	0.0																									ESRP1 p.L320F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2215_splice	0.2857	42.0	0.0	0.0																									NF1 p.X2215_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.L502Q	0.6333	60.0	0.0	0.0																									RUNX1T1 p.L502Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.L507*	0.3574	277.0	0.0	0.0																									MLH1 p.L507* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A1QA-06A-11D-A196-08	TCGA-D3-A1QA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.V144I	0.5	124.0	0.0	0.0																									NTRK1 p.V144I (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G395R	0.4	30.0	0.0	0.0																									IL12RB1 p.G395R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1933K	0.439	41.0	0.0	0.0																									ROS1 p.E1933K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.X1634_splice	0.3043	69.0	0.0	0.0																									ROS1 p.X1634_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1440S	0.3333	81.0	0.0	0.0																									ROS1 p.P1440S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T1384S	0.2889	45.0	0.0	0.0																									ROS1 p.T1384S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R493C	0.3836	73.0	0.0	0.0																									ROS1 p.R493C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.V490I	0.4333	60.0	0.0	0.0																									RUNX1T1 p.V490I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.M486I	0.4091	66.0	0.0	0.0																									RUNX1T1 p.M486I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R483K	0.5135	74.0	0.0	0.0																									RUNX1T1 p.R483K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.5838	173.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E718K	0.4717	106.0	0.0	0.0																									FGFR2 p.E718K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G356R	0.2626	99.0	0.0	0.0																									NTRK3 p.G356R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P366S	0.9155	71.0	0.0	0.0																									COL1A1 p.P366S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R326W	0.3404	47.0	0.0	0.0																									BRD4 p.R326W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R486C	0.431	116.0	0.0	0.0																									EWSR1 p.R486C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.Q2007*	0.2841	176.0	0.0	0.0																									MTOR p.Q2007* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.R44C	0.3333	24.0	0.0	0.0																									EPCAM p.R44C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D242N	0.1852	27.0	0.0	0.0																									NTRK3 p.D242N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1185L	0.2222	45.0	0.0	0.0																									COL1A1 p.P1185L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S796L	0.2553	47.0	0.0	0.0																									BRD4 p.S796L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.R59C	0.1935	31.0	0.0	0.0																									IL12RB1 p.R59C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.G142E	0.2258	62.0	0.0	0.0																									TMPRSS2 p.G142E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.G23D	0.3	40.0	0.0	0.0																									CDKN2A p.G23D (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R149C	0.1529	85.0	0.0	0.0																									RUNX1T1 p.R149C (Missense)		SKCM_SOMATICSNIPER	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G126E	0.5319	47.0	0.0	0.0																									ROS1 p.G126E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D576N	0.7027	37.0	0.0	0.0																									NTRK3 p.D576N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1822*	0.4463	121.0	0.0	0.0																									NF1 p.Q1822* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1149W	0.4894	94.0	0.0	0.0																									BRD4 p.R1149W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.G199E	0.2929	140.0	0.0	0.0																									TMPRSS2 p.G199E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P551L	0.4894	94.0	0.0	0.0																									MTOR p.P551L (Missense)		SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.R107W	0.3284	67.0	0.0	0.0																									PMS2 p.R107W (Missense)		SKCM_SOMATICSNIPER	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1754F	0.2195	41.0	0.0	0.0																									NF1 p.S1754F (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1857K	0.8734	79.0	0.0	0.0																									MTOR p.E1857K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.D223N	0.3667	60.0	0.0	0.0																									CCND3 p.D223N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1707N	0.8909	55.0	0.0	0.0																									ROS1 p.S1707N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R475Q	0.5309	194.0	0.0	0.0																									FGFR1 p.R475Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D44N	0.4937	79.0	0.0	0.0																									RUNX1T1 p.D44N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P453S	0.6078	487.0	0.0	0.0																									ESRP1 p.P453S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.8084	167.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G690R	0.25	36.0	0.0	0.0																									FGFR2 p.G690R (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1108S	0.3871	31.0	0.0	0.0																									ROS1 p.P1108S (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q8-06A-11D-A19A-08	TCGA-D3-A1Q8-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.2326	43.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CRKL	Nonsense	p.Q31*	0.2055	73.0	0.0	0.0																									CRKL p.Q31* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.D232N	0.3803	71.0	0.0	0.0																									EPCAM p.D232N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.S313L	0.3404	47.0	0.0	0.0																									AURKB p.S313L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.V88A	0.3077	52.0	0.0	0.0																									POT1 p.V88A (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A195-06A-11D-A196-08	TCGA-ER-A195-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2272V	0.3333	63.0	0.0	0.0																									MTOR p.A2272V (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P73L	0.2596	104.0	0.0	0.0																									RUNX1T1 p.P73L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G371E	0.2469	81.0	0.0	0.0																									ESRP1 p.G371E (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1232A	0.2752	109.0	0.0	0.0																									NF1 p.P1232A (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.H458Y	0.2703	148.0	0.0	0.0																									TPX2 p.H458Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P2049L	0.5	20.0	0.0	0.0																									ROS1 p.P2049L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.R563*	0.3851	174.0	0.0	0.0																									PMS2 p.R563* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.D928N	0.3158	76.0	0.0	0.0																									MTOR p.D928N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51N-06A-11D-A25O-08	TCGA-D3-A51N-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S697F	0.2022	183.0	0.0	0.0																									TACC3 p.S697F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S796F	0.3952	124.0	0.0	0.0																									FGFR2 p.S796F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S383F	0.4444	72.0	0.0	0.0																									FLI1 p.S383F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.Y834N	0.2712	118.0	0.0	0.0																									NTRK3 p.Y834N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G626S	0.459	61.0	0.0	0.0																									IL12RB1 p.G626S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.2442	86.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.H458Y	0.3981	108.0	0.0	0.0																									TPX2 p.H458Y (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A1033V	0.2268	97.0	0.0	0.0																									PDGFRB p.A1033V (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2271R	0.3077	52.0	0.0	0.0																									ROS1 p.G2271R (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E357K	0.2214	131.0	0.0	0.0																									ESRP1 p.E357K (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	COL1A1	Splice Site	p.X35_splice	0.4832	149.0	0.0	0.0																									COL1A1 p.X35_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G658S	0.5	112.0	0.0	0.0																									ROS1 p.G658S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S799F	0.2958	71.0	0.0	0.0																									FGFR2 p.S799F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P223T	0.2647	68.0	0.0	0.0																									ERG p.P223T (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZM-06A-12D-A197-08	TCGA-FS-A1ZM-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R2230K	0.5263	38.0	0.0	0.0																									ROS1 p.R2230K (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.T207I	0.7381	42.0	0.0	0.0																									NTRK2 p.T207I (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2132N	0.3158	114.0	0.0	0.0																									ROS1 p.S2132N (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.P34L	0.2226	283.0	0.0	0.0																									POT1 p.P34L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q5-06A-11D-A196-08	TCGA-D3-A1Q5-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.L40F	0.335	206.0	0.0	0.0																									MDM2 p.L40F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S808L	0.2917	48.0	0.0	0.0																									ROS1 p.S808L (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.G216R	0.45	60.0	0.0	0.0																									AURKA p.G216R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	EPCAM	Splice Site	p.X220_splice	0.3276	58.0	0.0	0.0																									EPCAM p.X220_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.G237R	0.2762	105.0	0.0	0.0																									EPCAM p.G237R (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.T395I	0.439	41.0	0.0	0.0																									CCNE1 p.T395I (Missense)		SKCM_SOMATICSNIPER	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P483L	0.2824	85.0	0.0	0.0																									FGFR1 p.P483L (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E546K	0.3947	38.0	0.0	0.0																									NTRK2 p.E546K (Missense)		SKCM_SOMATICSNIPER	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R692C	0.2346	81.0	0.0	0.0																									NTRK1 p.R692C (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P1042L	0.5424	59.0	0.0	0.0																									PDGFRB p.P1042L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P1042S	0.55	60.0	0.0	0.0																									PDGFRB p.P1042S (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G687R	0.4189	74.0	0.0	0.0																									PDGFRB p.G687R (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E621K	0.3771	175.0	0.0	0.0																									ROS1 p.E621K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1750V	0.2778	72.0	0.0	0.0																									ROS1 p.A1750V (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q237*	0.3295	88.0	0.0	0.0																									ROS1 p.Q237* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.T228I	0.4151	53.0	0.0	0.0																									CCNE1 p.T228I (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S2496F	0.1828	93.0	0.0	0.0																									NF1 p.S2496F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P817L	0.2254	71.0	0.0	0.0																									COL1A1 p.P817L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.S513F	0.2958	71.0	0.0	0.0																									COL1A1 p.S513F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.6393	61.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-ER-A19D-06A-11D-A197-08	TCGA-ER-A19D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L2155F	0.4043	47.0	0.0	0.0																									ROS1 p.L2155F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A337T	0.4375	32.0	0.0	0.0																									NTRK1 p.A337T (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I7-06A-22D-A197-08	TCGA-DA-A1I7-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1579K	0.3404	47.0	0.0	0.0																									ROS1 p.R1579K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I7-06A-22D-A197-08	TCGA-DA-A1I7-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.835	206.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E234K	0.4211	95.0	0.0	0.0																									COL1A1 p.E234K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E402K	0.6567	300.0	0.0	0.0																									ROS1 p.E402K (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.5972	72.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S795F	0.2364	55.0	0.0	0.0																									PDGFRB p.S795F (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S543F	0.4683	504.0	0.0	0.0																									ESRP1 p.S543F (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R220Q	0.2787	122.0	0.0	0.0																									COL1A1 p.R220Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P335S	0.2195	82.0	0.0	0.0																									TMPRSS2 p.P335S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.F360S	0.2453	53.0	0.0	0.0																									RAF1 p.F360S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.2623	122.0	0.0	0.0																									CDKN2A p.P48L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48S	0.2252	111.0	0.0	0.0																									CDKN2A p.P48S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.G881R	0.2949	78.0	0.0	0.0																									RB1 p.G881R (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1395*	0.3542	96.0	0.0	0.0																									NF1 p.Q1395* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P46S	0.3178	107.0	0.0	0.0																									BRD4 p.P46S (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E527K	0.4912	57.0	0.0	0.0																									ROS1 p.E527K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.G449E	0.3462	26.0	0.0	0.0																									RB1 p.G449E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.A562E	0.4211	19.0	0.0	0.0																									RB1 p.A562E (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.S304F	0.4667	30.0	0.0	0.0																									NTRK1 p.S304F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.4067	150.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A51B-01A-11D-A27K-08	TCGA-EB-A51B-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.N529D	0.2895	76.0	0.0	0.0																									ESRP1 p.N529D (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A51B-01A-11D-A27K-08	TCGA-EB-A51B-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.9	20.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A51B-01A-11D-A27K-08	TCGA-EB-A51B-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G169R	0.3333	60.0	0.0	0.0																									NTRK1 p.G169R (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1569W	0.2973	37.0	0.0	0.0																									ROS1 p.R1569W (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L368I	0.75	32.0	0.0	0.0																									ROS1 p.L368I (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.7882	170.0	0.0	0.0																									CDKN2A p.P48L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.D142N	0.3676	204.0	0.0	0.0																									FGFR2 p.D142N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2143_splice	0.5	66.0	0.0	0.0																									NF1 p.X2143_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-XV-A9W2-01A-11D-A397-08	TCGA-XV-A9W2-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S470F	0.3958	96.0	0.0	0.0																									PDGFRB p.S470F (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P751S	0.4352	108.0	0.0	0.0																									EML4 p.P751S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2305K	0.4737	76.0	0.0	0.0																									ROS1 p.E2305K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.K228E	0.459	61.0	0.0	0.0																									EML4 p.K228E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G641E	0.4017	361.0	0.0	0.0																									COL1A1 p.G641E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.K768E	0.2171	152.0	0.0	0.0																									NTRK3 p.K768E (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X654_splice	0.2143	56.0	0.0	0.0																									RB1 p.X654_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A1Q7-06A-11D-A19A-08	TCGA-D3-A1Q7-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P569S	0.32	25.0	0.0	0.0																									BRD4 p.P569S (Missense)		SKCM_SOMATICSNIPER	TCGA-HR-A2OG-06A-21D-A197-08	TCGA-HR-A2OG-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E590K	0.5147	68.0	0.0	0.0																									NTRK3 p.E590K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1143L	0.6667	36.0	0.0	0.0																									BRD4 p.P1143L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P1001S	0.3579	95.0	0.0	0.0																									PDGFRB p.P1001S (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.K39E	0.323	226.0	0.0	0.0																									POT1 p.K39E (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.4186	43.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P382S	0.6923	26.0	0.0	0.0																									FLI1 p.P382S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G227E	0.68	50.0	0.0	0.0																									FGFR2 p.G227E (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S1641F	0.3826	115.0	0.0	0.0																									MTOR p.S1641F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1333K	0.5385	39.0	0.0	0.0																									ROS1 p.E1333K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.6565	262.0	0.0	0.0																									CDKN2A p.P48L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E695K	0.2807	57.0	0.0	0.0																									FGFR2 p.E695K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L11F	0.3846	91.0	0.0	0.0																									BRD4 p.L11F (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	EWSR1	Nonsense	p.Q249*	0.375	40.0	0.0	0.0																									EWSR1 p.Q249* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G552E	0.403	67.0	0.0	0.0																									FGFR2 p.G552E (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E88K	0.3913	69.0	0.0	0.0																									LIMK2 p.E88K (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFB	Splice Site	p.X153_splice	0.2727	77.0	0.0	0.0																									PDGFB p.X153_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D9-A6E9-06A-12D-A30X-08	TCGA-D9-A6E9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2131D	0.3643	140.0	0.0	0.0																									ROS1 p.E2131D (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P241S	0.2963	27.0	0.0	0.0																									PMS2 p.P241S (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.3235	34.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P81L	0.36	175.0	0.0	0.0																									CDKN2A p.P81L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2088F	0.3945	109.0	0.0	0.0																									ROS1 p.S2088F (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.H845Y	1.0	6.0	0.0	0.0																									PMS2 p.H845Y (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Nonsense	p.R486*	0.35	60.0	0.0	0.0																									IL12RB1 p.R486* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G327E	0.2821	39.0	0.0	0.0																									ROS1 p.G327E (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.S889F	0.4583	24.0	0.0	0.0																									COL1A1 p.S889F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Nonsense	p.W460*	0.3636	22.0	0.0	0.0																									ERG p.W460* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S158F	0.2231	130.0	0.0	0.0																									TACC3 p.S158F (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA3-06A-11D-A38G-08	TCGA-WE-AAA3-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2265K	0.4043	47.0	0.0	0.0																									ROS1 p.E2265K (Missense)		SKCM_SOMATICSNIPER	TCGA-WE-AAA3-06A-11D-A38G-08	TCGA-WE-AAA3-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D1003N	0.4674	92.0	0.0	0.0																									PDGFRB p.D1003N (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Nonsense	p.R849*	0.4098	61.0	0.0	0.0																									PDGFRB p.R849* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.L585F	0.388	250.0	0.0	0.0																									PMS2 p.L585F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S451F	0.7266	139.0	0.0	0.0																									FGFR1 p.S451F (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.H407Y	0.2664	214.0	0.0	0.0																									NF1 p.H407Y (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q756*	0.4857	70.0	0.0	0.0																									NF1 p.Q756* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E352K	0.72	75.0	0.0	0.0																									BRD4 p.E352K (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S436F	0.2558	43.0	0.0	0.0																									FGFR1 p.S436F (Missense)		SKCM_SOMATICSNIPER	TCGA-GN-A4U5-01A-11D-A32N-08	TCGA-GN-A4U5-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.L52P	0.2985	67.0	0.0	0.0																									EML4 p.L52P (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A2322T	0.9714	35.0	0.0	0.0																									ROS1 p.A2322T (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2294F	0.8824	51.0	0.0	0.0																									ROS1 p.S2294F (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1539S	0.6957	23.0	0.0	0.0																									ROS1 p.P1539S (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.W354*	0.4406	143.0	0.0	0.0																									RUNX1T1 p.W354* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R147G	0.2393	117.0	0.0	0.0																									RUNX1T1 p.R147G (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.4483	58.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.4074	27.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.K47R	0.3684	19.0	0.0	0.0																									FLI1 p.K47R (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.G311*	0.8548	62.0	0.0	0.0																									NF1 p.G311* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E435K	0.9375	32.0	0.0	0.0																									COL1A1 p.E435K (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1228C	0.5641	39.0	0.0	0.0																									BRD4 p.R1228C (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.C674W	0.2031	64.0	0.0	0.0																									BRD4 p.C674W (Missense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	LIMK2	Nonsense	p.R364*	0.4375	16.0	0.0	0.0																									LIMK2 p.R364* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1768L	0.2569	109.0	0.0	0.0																									ROS1 p.S1768L (Missense)		SKCM_SOMATICSNIPER	TCGA-FR-A44A-06A-11D-A24R-08	TCGA-FR-A44A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	RAF1	Nonsense	p.S287*	0.3134	67.0	0.0	0.0																									RAF1 p.S287* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G812D	0.411	73.0	0.0	0.0																									COL1A1 p.G812D (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P46S	0.2632	209.0	0.0	0.0																									BRD4 p.P46S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TPX2	Nonsense	p.R543*	0.2984	124.0	0.0	0.0																									TPX2 p.R543* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P422L	0.2741	135.0	0.0	0.0																									LIMK2 p.P422L (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2416V	0.5155	97.0	0.0	0.0																									MTOR p.A2416V (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H658Q	0.2449	49.0	0.0	0.0																									NTRK3 p.H658Q (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A110V	0.5125	80.0	0.0	0.0																									NTRK1 p.A110V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1293F	0.2933	75.0	0.0	0.0																									ROS1 p.S1293F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.S1273*	0.4464	56.0	0.0	0.0																									ROS1 p.S1273* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P9S	0.3354	161.0	0.0	0.0																									ROS1 p.P9S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.G176V	0.4088	159.0	0.0	0.0																									POT1 p.G176V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R31C	0.549	102.0	0.0	0.0																									RUNX1T1 p.R31C (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.W195*	0.6111	90.0	0.0	0.0																									RB1 p.W195* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1870Q	0.5676	37.0	0.0	0.0																									NF1 p.R1870Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1870_splice	0.5789	38.0	0.0	0.0																									NF1 p.X1870_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P621L	0.2157	102.0	0.0	0.0																									COL1A1 p.P621L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S769F	0.4182	55.0	0.0	0.0																									PMS2 p.S769F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JO-06A-11D-A196-08	TCGA-D3-A2JO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R316Q	0.3567	171.0	0.0	0.0																									RUNX1T1 p.R316Q (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.P322L	0.3375	160.0	0.0	0.0																									MDM2 p.P322L (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.Q255*	0.3824	34.0	0.0	0.0																									NTRK3 p.Q255* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P176R	0.44	75.0	0.0	0.0																									EWSR1 p.P176R (Missense)		SKCM_SOMATICSNIPER	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E402K	0.3281	570.0	0.0	0.0																									ROS1 p.E402K (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19C-06A-11D-A196-08	TCGA-ER-A19C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1114M	0.3333	18.0	0.0	0.0																									NF1 p.L1114M (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S126F	0.2063	63.0	0.0	0.0																									IL12RB1 p.S126F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.P32S	0.2586	58.0	0.0	0.0																									AURKA p.P32S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.H245Y	0.5439	57.0	0.0	0.0																									POT1 p.H245Y (Missense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R1362*	0.391	156.0	0.0	0.0																									NF1 p.R1362* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.5156	225.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-D3-A2JD-06A-11D-A19A-08	TCGA-D3-A2JD-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P551L	0.4	115.0	0.0	0.0																									MTOR p.P551L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A20B-06A-11D-A196-08	TCGA-EE-A20B-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.55	60.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A20B-06A-11D-A196-08	TCGA-EE-A20B-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A101V	0.2778	36.0	0.0	0.0																									MTOR p.A101V (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G166R	0.2308	78.0	0.0	0.0																									NTRK1 p.G166R (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.G429E	0.1882	85.0	0.0	0.0																									FLI1 p.G429E (Missense)		SKCM_SOMATICSNIPER	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.T786A	0.3469	98.0	0.0	0.0																									PDGFRB p.T786A (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S602F	0.2889	45.0	0.0	0.0																									FGFR1 p.S602F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R455*	0.3889	18.0	0.0	0.0																									RB1 p.R455* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R579*	0.2969	64.0	0.0	0.0																									RB1 p.R579* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L844F	0.5	44.0	0.0	0.0																									NF1 p.L844F (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1870Q	0.3443	61.0	0.0	0.0																									NF1 p.R1870Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1870_splice	0.339	59.0	0.0	0.0																									NF1 p.X1870_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P649S	0.3208	53.0	0.0	0.0																									BRD4 p.P649S (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E600K	0.381	21.0	0.0	0.0																									RUNX1T1 p.E600K (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S128L	0.1986	141.0	0.0	0.0																									PMS2 p.S128L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.P59S	0.3947	38.0	0.0	0.0																									MYC p.P59S (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A4P0-01A-41D-A25O-08	TCGA-EB-A4P0-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.F264I	0.6296	81.0	0.0	0.0																									PDGFRB p.F264I (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R243Q	0.3786	140.0	0.0	0.0																									RUNX1T1 p.R243Q (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.5909	22.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A51J-06A-11D-A25O-08	TCGA-D3-A51J-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A795V	0.3115	61.0	0.0	0.0																									TACC3 p.A795V (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6024	83.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.D23N	0.52	25.0	0.0	0.0																									PDGFB p.D23N (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D776N	0.4123	114.0	0.0	0.0																									PDGFRB p.D776N (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-AA3S-06A-11D-A397-08	TCGA-Z2-AA3S-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.G108R	0.5405	37.0	0.0	0.0																									ERG p.G108R (Missense)		SKCM_SOMATICSNIPER	TCGA-Z2-AA3S-06A-11D-A397-08	TCGA-Z2-AA3S-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E762K	0.2656	64.0	0.0	0.0																									NTRK3 p.E762K (Missense)		SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P27L	0.25	28.0	0.0	0.0																									TMPRSS2 p.P27L (Missense)		SKCM_SOMATICSNIPER	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T2207I	0.284	81.0	0.0	0.0																									MTOR p.T2207I (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P59L	0.1771	96.0	0.0	0.0																									RUNX1T1 p.P59L (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R31C	0.2338	77.0	0.0	0.0																									RUNX1T1 p.R31C (Missense)		SKCM_SOMATICSNIPER	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.W392*	0.5	144.0	0.0	0.0																									RUNX1T1 p.W392* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-EE-A29Q-06A-11D-A197-08	TCGA-EE-A29Q-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D477N	0.3607	61.0	0.0	0.0																									RUNX1T1 p.D477N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A5GL-06A-11D-A27K-08	TCGA-D3-A5GL-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	MTOR	Splice Site	p.X2483_splice	0.437	119.0	0.0	0.0																									MTOR p.X2483_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S218F	0.3622	127.0	0.0	0.0																									MLH1 p.S218F (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E364K	0.6129	31.0	0.0	0.0																									PDGFRB p.E364K (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S74N	0.5	52.0	0.0	0.0																									IL12RB1 p.S74N (Missense)		SKCM_SOMATICSNIPER	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1662*	0.1791	134.0	0.0	0.0																									NF1 p.W1662* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-DA-A95V-06A-11D-A372-08	TCGA-DA-A95V-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.R70S	0.1803	61.0	0.0	0.0																									ERG p.R70S (Missense)		SKCM_SOMATICSNIPER	TCGA-DA-A95V-06A-11D-A372-08	TCGA-DA-A95V-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E88*	0.7172	145.0	0.0	0.0																									CDKN2A p.E88* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-FS-A1YW-06A-11D-A197-08	TCGA-FS-A1YW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1427K	0.5649	131.0	0.0	0.0																									MTOR p.E1427K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R103G	0.25	28.0	0.0	0.0																									MTOR p.R103G (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.3699	73.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.X1789_splice	0.6774	31.0	0.0	0.0																									ROS1 p.X1789_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1009K	0.1774	62.0	0.0	0.0																									ROS1 p.E1009K (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R243Q	0.6214	140.0	0.0	0.0																									RUNX1T1 p.R243Q (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P176S	0.6038	53.0	0.0	0.0																									RUNX1T1 p.P176S (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L360F	0.187	123.0	0.0	0.0																									ESRP1 p.L360F (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.7143	14.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.F105L	0.3256	86.0	0.0	0.0																									NTRK2 p.F105L (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.T176I	0.25	68.0	0.0	0.0																									POLE2 p.T176I (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D836H	0.5122	41.0	0.0	0.0																									NTRK3 p.D836H (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.5227	132.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2355_splice	0.1695	59.0	0.0	0.0																									NF1 p.X2355_splice (Splice Site)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.N2780D	0.2213	122.0	0.0	0.0																									NF1 p.N2780D (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G353R	0.3049	82.0	0.0	0.0																									IL12RB1 p.G353R (Missense)		SKCM_SOMATICSNIPER	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.Q660L	0.3148	54.0	0.0	0.0																									NTRK1 p.Q660L (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.H86Y	0.3281	64.0	0.0	0.0																									PAK1 p.H86Y (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24S	0.8667	30.0	0.0	0.0																									CDK4 p.R24S (Missense)		SKCM_SOMATICSNIPER	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1129T	0.6538	26.0	0.0	0.0																									ROS1 p.R1129T (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.G629R	0.9839	62.0	0.0	0.0																									NF1 p.G629R (Missense)		SKCM_SOMATICSNIPER	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P60L	0.2892	83.0	0.0	0.0																									TPX2 p.P60L (Missense)		SKCM_SOMATICSNIPER	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 p.X343_splice (Splice Site), ESRP1 p.R264* (Nonsense), DOCK3 p.W1033* (Nonsense), POLE p.X1021_splice (Splice Site), MSH3 p.Q46* (Nonsense), RNF43 p.Q577* (Nonsense), DOCK3 p.Q1050* (Nonsense), MSH2 p.Q462* (Nonsense), DOCK3 p.R719* (Nonsense), RNF43 p.Q563* (Nonsense), DOCK3 p.X1135_splice (Splice Site), MSH2 p.R680* (Nonsense), MLH1 p.L507* (Nonsense), PRDM2 p.Q1435* (Nonsense), PMS2 p.R563* (Nonsense), ACVR2A p.K447* (Nonsense), ACVR2A p.Q378* (Nonsense), MSH2 p.Q395* (Nonsense), JAK1 p.E765* (Nonsense)																													Supporting variants: MSH3 p.X343_splice (Splice Site), ESRP1 p.R264* (Nonsense), DOCK3 p.W1033* (Nonsense), POLE p.X1021_splice (Splice Site), MSH3 p.Q46* (Nonsense), RNF43 p.Q577* (Nonsense), DOCK3 p.Q1050* (Nonsense), MSH2 p.Q462* (Nonsense), DOCK3 p.R719* (Nonsense), RNF43 p.Q563* (Nonsense), DOCK3 p.X1135_splice (Splice Site), MSH2 p.R680* (Nonsense), MLH1 p.L507* (Nonsense), PRDM2 p.Q1435* (Nonsense), PMS2 p.R563* (Nonsense), ACVR2A p.K447* (Nonsense), ACVR2A p.Q378* (Nonsense), MSH2 p.Q395* (Nonsense), JAK1 p.E765* (Nonsense)		SKCM_SOMATICSNIPER		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.953																													COSMIC Signature (version 2) 7 (95%)		SKCM_SOMATICSNIPER		
